☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes ☒ No

As of ~~May~~August 10, 2019, there were ~~19,277,545~~28,349,745 shares of common stock outstanding.

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations, financial performance and condition as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained in this Quarterly Report on Form 10-Q that are not of historical facts may be deemed to be forward-looking statements. The forward-looking statements are contained principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about:

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “aims,” “assumes,” “goal,” “intends,” “objective,” “potential,” “positioned,” “target,” “continue,” “seek,” “vision” and similar expressions intended to identify forward-looking statements.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may later become inaccurate. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the “Risk Factors” section (which incorporates by reference to our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC), that could cause actual results or events to differ materially from the forward-looking statements that we make.

You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to our Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “GI Dynamics,” “the Company,” “we,” “us” and “our” refer to GI Dynamics, Inc. and its consolidated direct and indirect subsidiaries.

Unless indicated otherwise in this Quarterly Report on Form 10-Q, all references to “$”, “US$” or “dollars” refer to United States dollars, the lawful currency of the United States of America. References to “A$” refer to Australian dollars, the lawful currency of the Commonwealth of Australia. References to “€” or “euros” means euros, the single currency of Participating Member States of the European Union.

EndoBarrier ® and various company logos are the trademarks of the Company, in the United States and other countries. All other trademarks and trade names mentioned in this Quarterly Report on Form 10-Q are the property of their respective owners.

	March 31,			December 31,			June 30,			December 31,
	2019			2018			2019			2018
Assets
Current assets:
Cash and cash equivalents	$	1,286		$	3,806		$	2,427		$	3,806
Restricted cash		30			30			30			30
Prepaid expenses and other current assets		556			530			734			530
Total current assets		1,872			4,366			3,191			4,366
Property and equipment, net		60			63			51			63
Right-of-use assets, net of amortization								497			—
Total assets	$	1,932		$	4,429		$	3,739		$	4,429
Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable	$	467		$	1,050		$	914		$	1,050
Accrued expenses		987			1,645			902			1,645
Short term debt to related party, net of debt discount		4,986			4,960			5,000			4,960
Derivative liabilities		883			51			14			51
Short term lease liabilities								179			—
Total current liabilities		7,323			7,706			7,009			7,706
Long term debt to related party, net of discount		326			168
Long term debt to related party, net of debt discount								—			168
Long term lease liabilities								318			—
Total liabilities		7,649			7,874			7,327			7,874
Commitments (Note 11)
Commitments
Stockholders’ deficit:
Preferred stock, $0.01 par value – 500,000 shares authorized; no shares issued and outstanding at March 31, 2019 and December 31, 2018		—			—
Common stock, $0.01 par value – 50,000,000 shares authorized at March 31, 2019 and December 31, 2018; and 19,277,545 shares issued and outstanding at March 31, 2019 and December 31, 2018		193			193
Preferred stock, $0.01 par value – 500,000 shares authorized; no shares issued and outstanding at June 30, 2019 and December 31, 2018								—			—
Common stock, $0.01 par value – 50,000,000 shares authorized; 19,277,545 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively								193			193
Common stock – subscribed but unissued, 9,072,197 shares								5,991			—
Additional paid-in capital		263,580			263,521			269,476			263,521
Accumulated deficit		(269,490	)		(267,159	)		(279,248	)		(267,159	)
Total stockholders’ deficit		(5,717	)		(3,445	)		(3,588	)		(3,445	)
Total liabilities and stockholders’ deficit	$	1,932		$	4,429		$	3,739		$	4,429

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months Ended March 31,						Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018			2019			2018
Operating expenses:
Research and development		810			373		$	810		$	254		$	1,620		$	627
Sales and marketing		16			204			6			312			22			516
General and administrative		1,344			1,185			1,393			855			2,737			2,040
Total operating expenses		2,170			1,762			2,209			1,421			4,379			3,183
Loss from operations		(2,170	)		(1,762	)		(2,209	)		(1,421	)		(4,379	)		(3,183	)

Other income (expense):
Interest income		3			7			—			9			3			16
Interest expense		(177	)		(81	)		(5,912	)		(207	)		(6,089	)		(288	)
Foreign exchange gain (loss)		(9	)		9			15			(2	)		6			8
Gain on write-off of accounts payable		29			—			61			—			90			—
Re-measurement of derivative liabilities		(1	)		1			(1,687	)		2			(1,688	)		3
Other income (expense), net		(155	)		(64	)		(7,523	)		(198	)		(7,678	)		(261	)
Loss before income tax expense		(2,325	)		(1,826	)
Loss before benefit from income taxes								(9,732	)		(1,619	)		(12,057	)		(3,444	)
(Benefit from) Provision for income taxes		6			(18	)		26			15			32			(3	)
Net loss	$	(2,331	)	$	(1,808	)	$	(9,758	)	$	(1,634	)	$	(12,089	)	$	(3,441	)

Basic and diluted net loss per common share	$	(0.12	)	$	(0.15	)	$	(0.51	)	$	(0.13	)	$	(0.63	)	$	(0.29	)
Weighted-average number of common shares used in basic and diluted net loss per common share		19,277,545			11,803,221			19,277,545			12,333,101			19,277,545			12,069,624

The accompanying notes are an integral part of these consolidated financial statements.

	Common Stock				Additional					Total			Common Stock				Common Stock subscribed but unissued
THREE MONTHS ENDED MARCH 2019	Shares		Par Value		Paid-in Capital		Accumulated Deficit			Stockholders' Deficit
Balance at January 1, 2019		19,277,545		193		263,521		(267,159	)		(3,445	)
THREE MONTHS ENDED JUNE 2019													Shares		Par Value		Shares		Carrying Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at April 1, 2019														19,277,545	$	193		—	$	—	$	263,580	$	(269,490	)	$	(5,717	)
Reclassification of derivative liabilities to additional paid-in capital upon stockholder approval														—		—		—		—		5,784		—			5,784
Conversion of notes payable to related party														—		—		9,072,197		5,991		—		—			5,991
2017 Note modification														—		—		—		—		55		—			55
Stock-based compensation expense		—		—		59		—			59			—		—		—		—		57		—			57
Net loss		—		—		—		(2,331	)		(2,331	)		—		—		—		—		—		(9,758	)		(9,758	)
Balance at March 31, 2019		19,277,545	$	193	$	263,580	$	(269,490	)	$	(5,717	)
Balance at June 30, 2019														19,277,545	$	193		9,072,197	$	5,991	$	269,476	$	(279,248	)	$	(3,588	)

	Common Stock				Additional					Total			Common Stock				Common Stock subscribed but unissued
THREE MONTHS ENDED MARCH 2018	Shares		Par Value		Paid-in Capital		Accumulated Deficit			Stockholders' Deficit
THREE MONTHS ENDED JUNE 2018													Shares		Par Value		Shares		Carrying Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at April 1, 2018														12,333,101	$	124		—	$	—	$	256,814	$	(260,929	)	$	(3,991	)
Beneficial conversion feature discount associated with 2018 Note														—		—		—		—		1,007		—			1,007
Relative fair value of warrant issued with 2018 Note														—		—		—		—		743		—			743
Stock-based compensation expense														—		—		—		—		35		—			35
Net loss														—		—		—		—		—		(1,634	)		(1,634	)
Balance at June 30, 2018														12,333,101	$	124		—	$	—	$	258,599	$	(262,562	)	$	(3,839	)

													Common Stock				Common Stock subscribed but unissued
SIX MONTHS ENDED JUNE 2019													Shares		Par Value		Shares		Carrying Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at January 1, 2019														19,277,545	$	193		—	$	—	$	263,521	$	(267,159	)	$	(3,445	)
Reclassification of derivative liabilities to additional paid-in capital upon stockholder approval														—		—		—		—		5,784		—			5,784
Conversion of notes payable to related party														—		—		9,072,197		5,991		—		—			5,991
2017 Note modification														—		—		—		—		55		—			55
Stock-based compensation expense														—		—		—		—		116		—			116
Net loss														—		—		—		—		—		(12,089	)		(12,089	)
Balance at June 30, 2019														19,277,545	$	193		9,072,197	$	5,991	$	269,476	$	(279,248	)	$	(3,588	)

													Common Stock				Common Stock subscribed but unissued
SIX MONTHS ENDED JUNE 2018													Shares		Par Value		Shares		Carrying Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Deficit
Balance at January 1, 2018		11,157,489		112		255,294		(259,121	)		(3,715	)		11,157,489	$	112		—	$	—	$	255,294	$	(259,121	)	$	(3,715	)
Issuance of shares upon private placement, net of issuance costs		1,175,612		12		1,491		—			1,503			1,175,612		12		—		—		1,491		—			1,503
Beneficial conversion feature discount associated with 2018 Note														—		—		—		—		1,007		—			1,007
Relative fair value of warrant issued with 2018 Note														—		—		—		—		743		—			743
Stock-based compensation expense		—		—		29		—			29			—		—		—		—		64		—			64
Net loss								(1,808	)		(1,808	)		—		—		—		—		—		(3,441	)		(3,441	)
Balance at March 31, 2018		12,333,101	$	124	$	256,814	$	(260,929	)	$	(3,991	)

Balance at June 30, 2018														12,333,101	$	124		—	$	—	$	258,599	$	(262,562	)	$	(3,839	)

	Three Months Ended March 31,						Six Months Ended June 30,
	2019			2018			2019			2018
Operating activities:
Net loss	$	(2,331	)	$	(1,808	)	$	(12,089	)	$	(3,441	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		8			11			17			11
Re-measurement of derivative liabilities								1,688			(3	)
Loss on disposal of leasehold improvements								—			2
Amortization of debt issuance costs non-cash interest expense		—			18			—			122
Non-cash interest expense		110			198			6,086			163
Accretion of debt discount		66			—
Stock-based compensation expense		59			29			116			64
Re-measurement of derivative liabilities		1			(1	)
Non-cash change in accrued compensation								(22	)		—
Changes in operating assets and liabilities:
Accounts receivable		—			40			—			40
Prepaid expenses and other current assets		(26	)		(29	)		(204	)		27
Accounts payable		(583	)		(353	)		(136	)		(484	)
Accrued expenses		(768	)		(79	)		(743	)		(43	)
Net cash used in operating activities		(3,464	)		(1,974	)		(5,287	)		(3,542	)
Investing activities
Purchases of property and equipment		(5	)		—			(5	)		—
Net cash used in investing activities		(5	)		—			(5	)		—
Financing activities
Proceeds from issuance of common stock, net of issuance costs		—			1,503			—			1,503
Debt issuance costs		(103	)		—			(87	)		(85	)
Proceeds from long term debt, related party		1,000			—
Proceeds from short term and long term debt, related party								4,000			1,750
Net cash provided by financing activities		897			1,503			3,913			3,168
Net decrease in cash and cash equivalents		(2,572	)		(471	)		(1,379	)		(374	)
Cash, cash equivalents and restricted cash at beginning of period		3,836			3,064			3,836			3,064
Cash, cash equivalents and restricted cash at end of period	$	1,264		$	2,593		$	2,457		$	2,690
Supplemental cash flow disclosures
Income taxes paid		6			11			32			23
Beneficial conversion feature discount associated with 2018 Note								—			1,007
Relative fair value of warrant issued with 2018 Note								—			743
Interest paid		394			—			394			—
Modification of 2017 Note								55			—
Right-of-use asset obtained in exchange for lease liability								509			—
Conversion of notes payable to related party								5,991			—
Reclassification of warrant from derivative liabilities to additional paid-in capital								5,784			—
Fair value of warrants issued with Notes to Related Party								4,072			—

The accompanying notes are an integral part of these consolidated financial statements.

GI Dynamics^® is a clinical stage medical device company focused on the development and commercialization of EndoBarrier, a medical device intended for treatment of patients with type 2 diabetes and obesity.

Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. According to the Centers for Disease Control and Prevention (CDC), people with type 2 diabetes represent 90% of the worldwide diabetes population, whereas 10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus in which not enough insulin is produced).

Being overweight is a condition where the patient’s body mass index (BMI) is greater than 25 (kg/m²); obesity is a condition where the patient’s BMI is greater than 30, according to the CDC. Obesity and its comorbidities contribute to the progression of type 2 diabetes. Many experts believe obesity contributes to higher levels of insulin resistance, which creates a feedback loop that increases the severity of type 2 diabetes.

When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes.

EndoBarrier^® is intended for the treatment of type 2 diabetes and obesity in a minimally invasive and reversible manner.

The current treatment paradigm for type 2 diabetes is lifestyle therapy combined with pharmacological treatment, whereby treating clinicians prescribe a treatment regimen of one to four concurrent medications that could include insulin for patients with higher levels of blood sugar. Insulin carries a significant risk of increased mortality and may contribute to weight gain, which in turn may lead to higher levels of insulin resistance and increased levels of blood sugar. Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled treatment gap.

Our vision is to make EndoBarrierthe essential nonpharmacological and non-anatomy-altering treatment for patients with type 2 diabetes and obesity. We intend to achieve this vision by providing a safe and effective device, focusing on optimal patient care, supporting treating clinicians, adding to the extensive body of clinical evidence around EndoBarrier, gaining appropriate regulatory approvals, continuing to improve our products and systems, operating the company in a lean fashion, and maximizing ~~shareholder~~stockholder value.

EndoBarrier^® is intended for the treatment of type 2 diabetes and obesity in a minimally invasive and reversible manner and is designed to mimic the mechanism of action of duodenal-jejunal exclusion created by gastric bypass surgery.

Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company currently operates in one reportable business segment.

In 2011, the Company began commercial sales of its product, EndoBarrier, which was approved and commercially available in multiple countries outside the U.S. at the time.

In 2013, the Company received approval from the U.S. Food and Drug Administration (“FDA”) to commence its initial pivotal trial of EndoBarrier (the “ENDO Trial”). The Company announced its decision to stop the ENDO Trial in the second half of fiscal year 2015 and thereafter announced that it was reducing headcount by approximately 46% as part of its efforts to restructure its business and expenses and to ensure sufficient cash remained available for it to establish new priorities, continue limited market development and research, and to evaluate strategic options.

In the second and third quarters of fiscal year 2016, the Company took additional actions that it thought necessary to ~~allow the opportunity to~~ evolve ~~its~~ strategic options. These actions resulted in non-recurring charges totaling approximately $1.1 million, including $0.4 million related to restructuring charges in our second quarter, $0.6 million related to employee departures in both our second and third quarters and $0.1 million related to ~~abandonment of~~the early exit from our former headquarters in Lexington, MA.

In October 2016, the Company received final cancellation notification from the Therapeutic Goods Administration (“TGA”) for the listing of EndoBarrier on the Australian Register of Therapeutic Goods (“ARTG”).

In May 2017, the Company received notification from its notified body, SGS United Kingdom Limited (“SGS”), that the CE Mark for EndoBarrier had been suspended pending closure of non-conformances related to its quality management system required under International Organization for Standardization (“ISO”) regulations.

On November 10, 2017, the Company received notification from SGS that SGS was withdrawing the Certificate of Conformance for EndoBarrier, ending the CE Marking of EndoBarrier in Europe and select Middle East countries.

In December 2017, the Company received notification from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) that all EndoBarrier delivery systems (liners) in inventory needed to be returned to the Company.

In August 2018, the Company received approval of an investigational device exemption (“IDE”) from the FDA to begin enrollment in a pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board (“IRB”) approval, which was received in February 2019.

From its inception in 2003 to its initial public offering (“IPO”) in 2011, the Company was financed by a series of preferred stock financings. In September 2011, the Company completed its IPO of common stock in the form of CHESS Depositary Interests (“CDIs”) in Australia. As a result of the IPO and simultaneous private placement in the U.S., the Company raised a total of approximately $72.5 million in proceeds, net of expenses and repayment of $6.0 million of the Company’s convertible term promissory notes. Additionally, in July and August 2013, the Company issued CDIs on the Australian Securities Exchange (“ASX”) through a private placement and share purchase plan, which raised a total of approximately $52.5 million, net of expenses. In May 2014, the Company raised an additional total of approximately $30.8 million, net of expenses, when it issued CDIs on the ASX through a private placement.

On December 20, 2016, the Company completed a private placement issue of 69,865,000 CDIs (1,397,300 shares) at an issue price of A$0.022 per CDI raising approximately $1.0 million, net of issuance costs. In January 2017, the Company completed the issue of 12,481,600 CDIs (249,632 shares) to eligible investors under a Security Purchase Plan for approximately $0.83 per share of common stock (A$0.022 per CDI) resulting in net proceeds after issuance costs of approximately $0.2 million.

In June 2017, the Company completed a Convertible Term Promissory Note (the “2017 Note”) secured financing with its largest ~~shareholder~~stockholder Crystal Amber Fund Limited (“Crystal Amber”) for a gross amount of $5.0 million. The 2017 Note accrues interest at 5% per annum compounded annually. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership position. The 2017 Note was originally due on December 31, 2018 and contains provisions for conversion during its term and is also subject to security arrangements in favor Crystal Amber (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In January and March 2018, the Company raised approximately $1.6 million in an offering of its CDIs to sophisticated and professional investors, including certain existing investors in Australia, the United States and the United Kingdom.

In May 2018, the Company completed a Convertible Term Promissory Note (the “2018 Note”) and Warrant (the “2018 Warrant”) financing with its largest ~~shareholder~~stockholder Crystal Amber for a gross amount of $1.75 million. The 2018 Note ~~accrues~~accrued annually compounded interest at 10% per annum ~~compounded annually.~~until its conversion into CDIs on June 30, 2019 (as described further below). The 2018 ~~Note matures and the 2018~~ Warrant ~~expires~~will expire on May 30, 2023. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership position. (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In September 2018, the Company received commitments for a private placement of approximately $5 million in an offering of its CDIs to sophisticated and professional investors, including certain existing investors in Australia, the United States and the United Kingdom. The first tranche of $2.2 million closed and cash was received in September 2018. The second and final tranche of $2.8 million was contingent upon ~~shareholder~~stockholder approval, which was obtained in October 2018. Cash proceeds from the second tranche were received in November 2018.

In December 2018, the maturity date of the 2017 Note was extended from December 31, 2018 to March 31, 2019 in exchange for payment of $394 thousand, the total accrued interest on the 2017 Note at December 31, 2018.

In March 2019, the Company completed a Convertible Term Promissory Note (the “March 2019 Note”) and Warrant (the “March 2019 Warrant”) financing with its largest ~~shareholder,~~stockholder, Crystal Amber, for a gross amount of $1.0 million. The March 2019 Note ~~accrues~~accrued annually compounded interest at 10% ~~per annum compounded annually.~~until its conversion into CDIs on June 30, 2019 (as described further below). Certain specific conversion terms ~~associated with the conversion of~~related to the March 2019 Note and issuance of the March 2019 Warrant ~~require shareholder~~required stockholder approval, which ~~will be sought in a vote of the stockholders of the Company~~was obtained during the Annual Meeting of Stockholders ~~anticipated to be~~ held ~~in May or~~on June ~~2019. The March~~30, 2019 ~~Note matures on March 15, 2024 and~~(at which stage the March 2019 Warrant ~~if issued,~~was immediately issued). The March 2019 Warrant will expire on ~~the fifth anniversary of the date of issuance.~~June 30, 2024. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership ~~position. (See~~position (see Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In March 2019, the maturity date of the 2017 Note was extended to May 1, 2019. In April 2019, the maturity date of the 2017 Note was extended to July 1, 2019. A further extension of the maturity date of the 2017 Note is described below.

~~computed~~May 10, 2019 and June 28, 2019, during which period 10% per annum interest was accrued on daily outstanding principal balances. Upon funding completion on June 28, 2019, accrued interest began to compound annually at a rate of 10% per annum until ~~the date upon which full funding under the May~~its conversion into CDIs on June 30, 2019 Note is anticipated to be received, regardless of whether full funding is made on such date (the “Full Funding Date”) and compounded annually beginning on the Full Funding Date. The $3.0 million payment will be made in several tranches.(as described further below). Certain specific terms associated with the conversion of the May 2019 Note and issuance of the May 2019 Warrant ~~require shareholder~~required stockholder approval, which ~~will be sought in a vote of the stockholders of the Company~~was obtained during the Annual Meeting of Stockholders ~~anticipated to be~~ held ~~in May or~~on June ~~2019. The May~~30, 2019 ~~Note matures and~~(at which stage the May 2019 Warrant ~~if issued,~~was immediately issued). The May 2019 Warrant will expire on ~~the fifth anniversary of the Full Funding Date.~~June 30, 2024. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership ~~position. (See~~position (see Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In June 2019, the maturity date of the 2017 Note was extended to October 1, 2019.

On June 30, 2019, Crystal Amber elected to convert the 2018 Note, the March 2019 Note and the May 2019 Note to CDIs. Under the terms of the respective notes, an aggregate of 453,609,963 CDIs (representing approximately 9,072,197 common shares) were subscribed but unissued on conversion and concurrent cancellation of the 2018 Note, the March 2019 Note and the May 2019 Note.

As of ~~March 31,~~June 30, 2019, the Company’s primary source of liquidity is its cash and cash equivalents balances. The Company continues to evaluate which markets are appropriate to pursue regulatory approvals, ~~continue pursuing~~pursue reimbursement, raise market awareness and conduct general market development and selling efforts. The Company continues to restructure its business and costs, establish new priorities, and evaluate strategic options. As a result, if the Company remains in business, it expects to incur significant operating losses for the next several years.

since inception and at ~~March 31,~~June 30, 2019 had an accumulated deficit of approximately ~~$270~~$279 million, a working capital deficit of approximately ~~$5.5~~$3.8 million, cash used in operating activities of approximately ~~$3.5~~$5.3 million and cash and cash equivalents of approximately ~~$1.3~~$2.5 million. Cash provided by these activities will be used predominantly to prepare for and conduct the Company’s clinical trial, which will result in increased expenses. The Company does not expect its current cash balances will be sufficient to operate beyond July 1, 2019 if cash is required to settle the 2017 Note on that date. Both parties to the 2017 Note are aware that if the Company is required to make this payment on the due date of July 1, 2019, the Company will be required either to renegotiate the due date of the loan or potentially cease operations. Crystal Amber and the Company are in discussions to extend of the due date of the 2017 Note, but there can be no assurance that any extension will occur. If the Company is able to amend the terms of the 2017 Note, it believes its cash and cash equivalents will be sufficient to fund operations to the end of ~~August 2019, or until the modified due date of the note.~~September 2019. The Company will need to raise additional funds through any combination of collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources.

Furthermore, if the Company raises insufficient funds and is required to make payment to Crystal Amber under the 2017 Note on its maturity date of October 1, 2019. the Company will be required either to renegotiate the maturity date of the loan or to potentially cease operations. The Company expects to discuss further extension of the maturity date of the 2017 Note with Crystal Amber, but there can be no assurance that any extension will occur.

The Company has no guaranteed source of capital that will sustain operations beyond ~~August~~September 2019. There can be no assurance that other potential financing opportunities will be available on acceptable terms, if at all. As such, if access to capital is not achieved to satisfy cash needs in the near term, the Company’s business, financial condition and results of operations will be materially harmed or the Company may be required to cease operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that ~~the~~these financial statements are issued.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements as of ~~March 31,~~June 30, 2019 and December 31, 2018 and the three and six months ended ~~March 31,~~June 30, 2019 and 2018 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued.

The accompanying interim consolidated financial statements and related disclosures as of ~~March 31,~~June 30, 2019, and for the three and six months ended ~~March 31,~~June 30, 2019 and 2018, are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K (“Form 10-K”), filed with the SEC on March 13, 2019. The December 31, 2018 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates its estimates, including those related to impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies, lease liabilities, valuation of derivative liabilities, estimates used to assess its ability to continue as a going concern and stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the

carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

The Company considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds and have a carrying amount that approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $4 thousand at ~~March 31,~~June 30, 2019 and $1.1 million at December 31, 2018.

The Company has $30 thousand in restricted cash used to secure a corporate credit card account.

When the Company resumes commercial activity, the Company will state inventory at the lower of first-in, first-out cost or net realizable value. When capitalizing inventory, the Company will consider factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product. At ~~March 31,~~June 30, 2019 and December 31, 2018, there was no inventory or reserves against inventory on the balance sheet.

Property and equipment, including leasehold improvements, are recorded at cost and are depreciated when placed in service using the straight-line method based on their estimated useful lives.

Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred.

Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining lease term. Costs for capital assets not yet placed into service ~~have been~~are capitalized as construction in progress and will be subsequently depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.

The Company adopted Accounting Standards Codification (“ASC”), Topic 842, Leases (“ASC 842”) on January 1, 2019, but had no long-term leases to which it would apply. In May 2019, the Company entered into the first Right of Use Lease requiring the adoption of Accounting Standards Codification (“ASC”), Topic 842, Leases (“ASC 842”).

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. Leases with a non-cancellable term greater than one year are recognized on the balance sheet as lease assets, short-term lease liabilities and long-term lease liabilities. Using criteria defined in ASC 842, the Company determines whether the lease is a Financing Lease or an Operating Lease.

Lease liabilities and their corresponding Right-of-Use assets are recorded based on the present value of lease payments over the expected remaining lease term. Options to renew an Operating lease are not included in the Company’s initial lease term assessment unless there is reasonable certainty that the Company will renew. However, certain adjustments to the Right-of-Use operating asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes an estimated incremental borrowing rate, which is the rate it is expected to incur to borrow an amount equal to the lease payments on a collateralized basis (or on an unsecured basis if existing debt covenants prevent further securitization) over a similar term in a similar economic environment.

In accordance with the guidance in ASC 842, components of a lease are split into lease components and non-lease components. A policy election is available pursuant to which an entity may elect to not separate lease and non-lease components. For new and amended leases beginning in 2019 and after, the Company has not made the election to combine lease and non-lease components.

Research and development costs are expensed when incurred. Research and development costs include costs of all basic research activities as well as other research, engineering, and technical effort required to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include preapproval regulatory and clinical trial ~~expenses.~~expenses incurred prior to regulatory approval.

The Company expenses as incurred all costs, including legal expenses, associated with obtaining patents until the patented technology becomes feasible. All costs incurred after the patented technology is feasible will be capitalized as an intangible asset. As of ~~March 31,~~June 30, 2019 and December 31, 2018, no such costs had been capitalized. The Company expensed no patent costs within general and administrative expenses inof $54 and $41 thousand for the ~~consolidated statements of operations~~three months ended June 30, 2019 and 2018, respectively, and $95 and $80 thousand for ~~each quarter~~the six months ended ~~March 31,~~June 30, 2019 and 2018, respectively.

We account for stock-based compensation in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 718, Stock Compensation, or ASC 718, which requires that stock-based compensation be measured and recognized as an expense in the financial statements and that such expense be measured at the grant date fair value.

For awards that vest based on service conditions, we use the straight-line method to allocate compensation expense to reporting periods. The grant date fair value of options granted is calculated using the Black-Scholes option pricing model, which requires the use of subjective assumptions including volatility, expected term and the fair value of the underlying Common Stock, among others.

The assumptions used in determining the fair value of stock-based awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change, and we use different assumptions, our stock-based compensation could be materially different in the future. The risk-free interest rate used for each grant is based on a zero-coupon U.S. Treasury instrument with a remaining term similar to the expected term of the stock-based award. Because we do not have a sufficient history to estimate the expected term, we use the simplified method for estimating the expected term. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. We estimate our expected stock volatility based on our to-date historical price volatility. We have not paid and do not anticipate paying cash dividends on our shares of Common Stock; therefore, the expected dividend yield is assumed to be zero. In 2017, the Company elected to use an actual occurrence method of recording award forfeitures rather than the prior standard of estimating forfeitures as of the grant date.

We periodically issue performance-based awards. For these awards, vesting will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, we expense the compensation of the stock award over the implicit service period.

Stock awards to non-employees are accounted for in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). The measurement date for non-employee awards is generally the date performance of services required from the non-employee is complete. For non-employee awards

that vest based on service conditions, the Company expenses the value of the awards over the related service period, provided they expect the service condition to be met. The Company records the expense of services rendered by non- employees based on the estimated fair value of the stock option using the Black-Scholes option pricing model over the contractual term of the non-employee. The fair value of unvested non-employee awards is remeasured at each reporting period and expensed over the vesting term of the underlying stock options on a straight-line basis.

The Company regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value.

In accordance with ASC 450, Contingencies, the Company accrues anticipated costs of settlement, damages, and losses for loss contingencies based on historical experience or to the extent specific losses are probable and estimable. Otherwise, the Company expenses these costs as incurred. If the estimate of a probable loss is a range, and no amount within the range is more likely, the Company accrues the minimum amount of the range.

The Company provides for income taxes under the liability method. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial reporting and the tax bases of assets and liabilities measured using the enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization.

The Company accounts for uncertain tax positions recognized in the consolidated financial statements by applying a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees.

As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.

The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.

For the three and six months ended ~~March 31,~~June 30, 2019 and 2018, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, no related reserves have been established.

The Company allocates issuance costs between the individual freestanding instruments identified on the same basis as proceeds were allocated. Issuance costs associated with the issuance of stock or equity contracts (i.e., equity-classified warrants and convertible preferred stock) are recorded as a charge against the gross proceeds of the offering. Any issuance costs associated with the issuance of liability-classified warrants are expensed as incurred. Issuance costs associated with the issuance of debt (i.e., convertible debt) is recorded as a direct reduction of the carrying amount of the debt liability but limited to the notional value of the debt. The Company accounts for debt as liabilities measured at amortized cost and amortizes the resulting debt discount to interest expense using the effective interest method over the expected term of the notes pursuant to ASC 835, Interest ("ASC 835"). To the extent that the reduction from issuance costs of the carrying amount of the debt liability would reduce the carrying amount below zero, such excess is recorded as interest expense.

The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt with Conversion and Other Options.” Under ~~the~~ ASC 470-20, an entity must separately account for the liability and equity components of the convertible debt instruments that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost.

The effect of ASC 470-20 on the accounting for our convertible debt instruments is that the equity component is required to be included in the additional paid-in capital section of stockholders’ equity on the consolidated balance sheets and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the notes. ~~As a result,~~Therefore, we are required to record as non-cash interest expense ~~as a result of~~ the amortization of the discounted carrying value of the convertible debt to ~~their~~the face amount over the term of the convertible debt. We report higher interest expense in our financial results because ASC 470-20 requires interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest.

For conventional convertible debt where the rate of conversion is below market value, the Company values and records a "beneficial conversion feature" ("BCF") and related debt ~~discount.~~discount on issuance. When the Company records a BCF, the relative fair value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid in capital) and amortized to interest expense over the life of the debt.

The Company evaluates events occurring after the date of its consolidated balance sheet for potential recognition or disclosure in its consolidated financial statements. ~~Other than the following, there~~There have been no material subsequent events that occurred through the date the Company issued its consolidated financial statements that require disclosure in or adjustment to its consolidated financial statements.

~~On April 22, 2019, the Company entered into a right of use lease (see Note 11).~~

~~On April 30, 2019, the Company entered into an amendment to its 2017 Note and Warrant Purchase Agreement and its 2017 Senior Secured Convertible Promissory Note (see Note 10).~~

~~On May 8, 2019, the Company entered into a Note and Warrant Purchase Agreement and issued a Senior Unsecured Convertible Promissory Note (see Notes 4 and 10).~~

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), or ASU 2016-02. ASU 2016-02 requires that lessees recognize in the statement of financial position for all leases (with the exception of short-term leases) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and a right-of-use asset, which is an asset representing the lessee’s right to use the underlying asset for the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. Lessees must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees may not apply a full retrospective transition approach. We have elected not to apply the guidance to short-term leases and the adoption of ASU 2016-02 has no impact on our consolidated financial statements as of December 31, 2018 and March 31, 2019 and for the three months ended March 31, 2019 and 2018.

~~In September 2017, the FASB issued ASU No. 2017-13,~~ Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments. ~~This new standard allows for an extension to certain public business entities to adopt the series of ASU’s defining revenue recognition and ASU 2016-02 regarding~~ ~~Leases. We qualify as a Public Business Entity and do not qualify for the extensions.~~

~~In June 2018, the FASB issued ASU No. 2018-07,~~ ~~Compensation – Stock Compensation (Topic 718)~~, or ASU 2018-07, which provides measurement provisions and clarifications for the accounting for Non-employee Share-Based Payments (“NESBP”). Changes within the amendments include grant-date fair value measurement of awards, probability adjustment of satisfying performance requirements for payment, and the elimination of the need to reclass awards on vesting. Additionally, ASU 2018-07 amends guidance specific to non-public entities, which do not apply given our status as a public entity. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted but not in advance of adoption of Topic 606. Remeasurement should only be performed on liability classified awards that have not been settled as of the date of adoption or which have no established measurement date. Remeasurement will result in an adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, those open awards are remeasured as of the date of adoption. The Company had no unvested or unearned NESBPs outstanding as of March 31, 2019.

In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements, or ASU 2018-09, which affects a wide variety of topics, including the following: Amendments to Subtopic 220-10, Income Statement— Reporting Comprehensive Income—Overall relates to income taxes not payable in cash; Amendments to Subtopic 470-50, Debt—Modifications and Extinguishments relates to debt extinguishment and requires that the net carrying amount of extinguished fair value elected debt equals its fair value at reacquisition and related gains or losses in other comprehensive income must be included in net income upon extinguishment of the debt; Amendments to Subtopic 480-10, Distinguishing Liabilities from Equity—Overall relates to combinations of freestanding financial instruments with non-controlling interests; Amendments to Subtopic 718-740, Compensation—Stock Compensation—Income Taxes relate to recognition timing clarification for excess tax benefits or deficiencies for compensation expense; Amendments to Subtopic 805-740, Business Combinations— Income Taxes relate to allocating tax provisions to an acquired entity; Amendments to Subtopic 815-10, Derivatives and Hedging— Overall relate to accounting for offsetting derivatives; Amendments to Subtopic 820-10, Fair Value Measurement— Overall

relate to the wording with respect to how transfer restrictions effect the fair value of an asset and adds explicit wording to allow entities to measure fair value on a net basis for those portfolios in which financial assets and financial liabilities and nonfinancial instruments are managed and valued together;

Amendments to Subtopic 940-405, Financial Services—Brokers and Dealers—Liabilities relate to guidance about offsetting on the balance sheet; and Amendments to Subtopic 962-325, Plan Accounting—Defined Contribution Pension Plans—Investments—Other relate to plan evaluation of whether a readily determinable fair value exists to determine whether those investments may qualify for the practical expedient to measure at net asset value in accordance with Topic 820. The transition and selection of an effective date is based on the facts and circumstances of each amendment, but many of the amendments have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. The Company is currently evaluating the relevance of each component and potential impact of ASU 2018-09 components on its consolidated financial statements.

In ~~July 2018, the FASB issued ASU No. 2018-11,~~ ~~Leases (Topic 842), Targeted Improvements~~, or ASU 2018-11, which primarily provides the ability to elect not to implement a modified retrospective presentation in the financial statements during transition periods and provides guidance to lessors on contract component separation. The Company declines the election and doing so has no impact on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13, which provides guidance focused on the disclosure requirements for disclosing fair value estimates, assumptions, and methodology. ~~Removed requirements~~Requirements removed include the requirement to disclose details around amount and reasoning for level 1 to level 2 transfers, timing policies for transfer between levels, and the valuation processes for level 3 fair value measurements. ~~Modified requirements~~Requirements modified include details regarding net asset redemption restrictions and timing related to uncertainty disclosures. ~~Added requirements to~~Requirement added include disclosures of changes in unrealized gains and losses for recurring level 3 measurements held as of the reporting date and disclosures around the range and weighted average of significant inputs used to develop level 3 fair value measurements. These amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty ~~should~~will be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments ~~should~~will be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of this ~~Update. An~~Update and an entity is permitted to early adopt any removed or modified disclosures upon issuance of this Update and delay adoption of the additional disclosures until their effective date. The Company has not elected early adoption and is currently evaluating the individual components and as these are disclosure refinements, expects no impact to its consolidated financial statements on adoption.

~~In March 2019, the FASB~~ ~~issued ASU No. 2019-01,~~ ~~Leases (Topic 842), Codification Improvements~~, or ASU 2019-01, which provides guidance focused on lessor accounting which is not applicable to us as we provide no leases to other parties, and also includes an explicit exception to a disclosure requirement for interim periods within the year of adoption. ASU 2019-01 has no impact on the Company’s quarterly consolidated financial statements.

Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During the three and six months ended ~~March 31,~~June 30, 2019 and 2018, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of ~~March 31,~~June 30, 2019 and 2018, as they would be anti-dilutive:

	Three Months Ended March 31,				As of June 30,
	2019		2018		2019		2018
Warrants to purchase common stock		3,552,672		28,532		8,277,081		1,972,976
Options to purchase common stock and other stock-based awards		1,545,719		1,668,219		1,545,719		1,668,219
Total		5,098,391		1,696,751		9,822,800		3,641,195

On May 4, 2016, the Company entered into a consulting agreement pursuant to which a consulting firm provides strategic advisory, finance, accounting, human resources and administrative functions, including chief financial officer services, to the Company. In connection with the consulting agreement, the Company granted the consulting firm a warrant (“Consultant Warrant”) to purchase up to 28,532 shares of the Company’s common stock at an exercise price per share equal to $0.64. The Consultant Warrant is fully vested and expires on May 4, 2021. The Company has reserved 28,532 shares of common stock related to the Consultant Warrant. As of ~~March 31,~~June 30, 2019, the Consultant Warrants had not been exercised.

On May 30, 2018, the Company entered into a Note and Warrant Purchase agreement that included a warrant to purchase 97,222,200 CDIs (representing 1,944,444 shares of common stock). The exercise price iswas initially US$0.018 per CDI and the exercise price was subsequently reset to US$0.0144 when the Company issued securities at the lower price in September 2018. The warrant can be exercised with cash or as a net exercise. The warrant iswas immediately exercisable on issuance and expires on May 30, 2023.

On March 15, 2019, the Company entered into a Note and Warrant Purchase agreement that included a form of warrant to purchase 78,984,823 CDIs (representing 1,579,696 shares of common stock). The ~~issuance of the~~ warrant ~~requires shareholder approval, which will be sought in a vote of the~~was subsequently approved by stockholders ~~of the Company during the Annual Meeting of Stockholders anticipated to be held in May or~~and issued on June 30, 2019. ~~If issued, the~~The warrant’s exercise price is US$0.0127 per CDI, and the warrant can be exercised with cash or as a net exercise. The warrant iswas immediately exercisable on issuance and will expire ~~(if issued)~~ on ~~the fifth anniversary~~June 30, 2024.

On May 8, 2019, the Company entered into a Note and Warrant Purchase agreement that included a form of warrant to purchase up to 236,220,472 CDIs (representing 4,724,409 shares of common stock), or a lesser number of CDIs ~~proportion~~proportional to the amount finally funded under the simultaneously issued $3 million note. The ~~issuance of~~Note was fully funded and the warrant ~~requires shareholder approval, which will be sought in a vote~~for the maximum number of ~~the~~CDIs was subsequently both approved by stockholders ~~of the Company during the Annual Meeting of Stockholders anticipated to be held in May or~~and issued on June 30, 2019. ~~If issued, the~~The warrant’s exercise price is US$0.0127 per CDI, and the warrant can be exercised with cash or as a net exercise. The warrant iswas immediately exercisable on issuance and will expire on ~~the fifth anniversary of the Full Funding Date (as defined in Note 1 to these Consolidated Financial Statements).~~

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of ~~March 31,~~June 30, 2019 and December 31, 2018 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability.

The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands):

			Fair Value Measurements at								Fair Value Measurements at
			Reporting Date Using								Reporting Date Using
			Quoted Prices in		Significant Other		Significant				Quoted Prices in		Significant Other		Significant
			Active Markets for		Observable		Unobservable				Active Markets for		Observable		Unobservable
			Identical Assets		Inputs		Inputs				Identical Assets		Inputs		Inputs
Description	March 31, 2019		(Level 1)		(Level 2)		(Level 3)		June 30, 2019		(Level 1)		(Level 2)		(Level 3)
Assets
Money market funds (included in cash and cash equivalents)	$	4	$	4	$	—	$	—	$	4	$	4	$	—	$	—
Total assets	$	4	$	4	$	—	$	—	$	4	$	4	$	—	$	—
Liabilities
Derivative liability	$	883	$	—	$	—	$	883	$	14	$	—	$	—	$	14
Total liabilities	$	883	$	—	$	—	$	883	$	14	$	—	$	—	$	14

The assumptions used in the Black-Scholes option pricing model to determine the fair value of the common stock warrants as of ~~March 31,~~June 30, 2019, and December 31, 2018 were as follows:

	March 31,			December 31,			June 30,			December 31,
	2019			2018			2019			2018
Exercise price (A$55.00 at the then current exchange rate)	$	0.64		$	0.64		$	0.64		$	0.64
Fair value of common stock	$	0.67		$	0.57		$	0.77		$	0.57
Expected volatility		179.0	%		134.0	%		169.0	%		134.0	%
Expected term (in years)	2.11			2.35			1.86			2.35
Risk-free interest rate		2.3	%		2.5	%		1.8	%		2.5	%
Expected dividend yield		—	%		—	%	0%			0%

The following table rolls forward the fair value of the Derivative Liabilities, where fair value is determined by Level 3 inputs (in thousands):

Balance at December 31, 2018	$	51		$	51
Increase in fair value of warrants upon re-measurement		1			1,715
Amortization of conversion rights		(40	)		(40	)
Fair value of warrants issued with 2019 Note		871
Balance at March 31, 2019	$	883
Fair value of warrants issued with Notes to Related Party					4,072
Reclassification of warrants to additional paid-in caputal					(5,784	)
Balance at June 30, 2019				$	14

Cash, cash equivalents, restricted cash, prepaid expenses and other current assets, right of use assets, accounts payable, accrued expenses, short-term lease liabilities and short-term debt to Crystal Amber Fund Limited, a related party, at ~~March 31,~~June 30, 2019 and December 31, 2018 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments. The carrying value of the Company’s long-term debt to Crystal Amber Fund Limited, a related party at ~~March 31, 2019 and~~ December 31, 2018, and long-term lease liabilities at June 30, 2019 approximates fair value based on commonly applied estimation methodologies, published market data and industry studies obtained by the Company.

Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and restricted cash. The Company maintains its cash and cash equivalent balances with high quality financial institutions, and consequently, while the balances may exceed federally insured limits, the Company believes that such funds are subject to minimal credit risk. The Company’s short-term investments potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to hold at least an A rating from a recognized credit rating agency, thereby reducing credit risk concentration.

~~The~~When the Company ~~grants~~had regulatory approval to sell EndoBarrier in select markets, the Company granted unsecured credit to customers in the normal course of ~~business but generally does not require collateral or any other security to support its receivables.~~business. The Company ~~makes~~made judgments as to its ability to collect outstanding receivables and ~~provides~~provided an allowance for receivables when collection ~~becomes~~became doubtful. Provisions ~~are~~were made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not individually reviewed. In certain circumstances, the Company allows customers to return defective or nonconforming products for credit or replacement products. Defective or nonconforming products typically include those products that resulted in an unsuccessful implant procedure. The Company records an estimate for product returns based upon historical trends. The associated reserve for product returns is recorded as a reduction of the Company’s accounts receivable. Amounts determined to be uncollectible are written off against the total reserve. ~~The~~After regulatory approval for EndoBarrier was suspended, the Company deemed certain remaining accounts receivable uncollectible and recorded write-offs of uncollectible accounts receivable of ~~$38~~$42 thousand in the ~~three~~six months ended ~~March 31,~~June 30, 2018. As of ~~March 31,~~June 30, 2019 and December 31, 2018, the Company had no accounts receivable and no reserves for uncollectible accounts receivable.

The following is a rollforward of the Company’s allowance for doubtful accounts (in thousands):

	Three Months Ended March 31,					Six Months Ended June 30,
	2019		2018			2019		2018
Beginning balance	$	—	$	42		$	—	$	42
Net charges to expenses		—		38			—		—
Utilization of allowances		—		(2	)		—		(42	)
Ending balance	$	—	$	78		$	—	$	—

The Company states inventory at the lower of first-in, first-out cost or net realizable value. The Company records a provision for excess, expired, and obsolete inventory based primarily on estimates of forecasted revenues. When capitalizing inventory, the Company considers factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product.

A significant change in the timing or level of demand for products as compared to forecasted amounts may result in recording additional provisions for excess, expired, and obsolete inventory in the future. Currently, the determination of obsolete or excess inventory requires the Company to estimate regulatory approval probability and timing and subsequent demand for its products within approved markets. The estimated future demand is compared

~~to inventory levels to determine the amount, if any, of obsolete and excess inventory. Given~~assessed the probability and timing of regulatory approval and appropriate inventory life span ~~we fully reserved our~~and deemed the inventory on hand as of December 31, 2017 to be obsolete and subsequently wrote off all inventory and reserves in ~~2018 as the materials on hand were not expected to be usable for future sales.~~2018. There is no inventory or reserves against inventory on the balance sheet at ~~March 31,~~June 30, 2019 and December 31, 2018, respectively.

	March 31,			December 31,			June 30,			December 31,
	2019			2018			2019			2018
Laboratory and manufacturing equipment	$	591		$	591		$	591		$	591
Computer equipment and software		1,187			1,182			1,187			1,182
Office furniture and equipment		183			183			183			183
		1,961			1,956			1,961			1,956
Less accumulated depreciation and amortization		(1,901	)		(1,893	)		(1,910	)		(1,893	)
Total	$	60		$	63		$	51		$	63

Depreciation and amortization expense of property and equipment totaled approximately $8$9 thousand and $0 for the three months ended June 30, 2019 and 2018, respectively and $17 and $11 thousand for the ~~three~~six months ended ~~March 31,~~June 30, 2019 and 2018, respectively.

At ~~March 31,~~June 30, 2019 and December 31, 2018, the Company had no property and equipment assets ~~under~~financed in any capital ~~lease.~~lease arrangement.

	March 31,		December 31,		June 30,		December 31,
	2019		2018		2019		2018
Payroll and related liabilities	$	167	$	386	$	259	$	386
Professional fees		434		573		312		573
Credit refunds		167		186		167		186
Interest		211		494		124		494
Other		8		6		40		6
Total	$	987	$	1,645	$	902	$	1,645

On June 15, 2017, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”). The Purchaser is a related party for ASX purposes and is the Company’s largest ~~shareholder.~~stockholder.

The 2017 Note accrues interest at a rate equal to 5% per annum, compounded annually, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on the original maturity date of December 31, 2018, but the maturity date was extended ~~to March 31, 2019 in December 2018 and further extended to May 1, 2019 in March 2019 and July 1, 2019 in April 2019.~~multiple times as described below.

The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, the Purchaser is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if the Purchaser were the absolute owner thereof.

The ASX provided the Company with a waiver to allow all asset liens (the “Security”) to be granted to the Purchaser without the normal requirement of having to obtain ~~shareholder~~stockholder approval for the grant of a security to a related party of the Company (which the Purchaser is for ASX purposes). As a result of the waiver, the Security contains a provision that provides that if an event of default occurs and the Purchaser exercises its rights under the Security, neither the Purchaser nor any of its associates can acquire any legal or beneficial interest in an asset of the Company or its subsidiaries in full or partial satisfaction of the Company’s obligations under the Security, or otherwise deal with the assets of the Company or its subsidiaries, without the Company first having complied with any applicable ASX Listing Rules, including ASX Listing Rule 10.1, other than as required by law or through a receiver, or receiver or manager (or analogous person) appointed by the Purchaser exercising its power of sale under the Security and selling the assets to an unrelated third party on arm’s length commercial terms and conditions and distributing the cash proceeds to the Purchaser or any of its associates in accordance with their legal entitlements.

The entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, (i) prior to the maturity date, at the option of the Purchaser at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing.

In the event that the Borrower issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective ~~optional conversion price (based on the five-day volume weighted average price on the ASX),~~Optional Conversion Price, the Purchaser has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that the Purchaser may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains the Purchaser’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing.

In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. If the consideration received for such change of control is a non-cash consideration, the Purchaser may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of the Purchaser.

The 2017 Note Purchase Agreement contains customary events of default including a failure to perform obligations under the 2017 Note Purchase Agreement, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 Note Purchase Agreement and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

The Company recorded the $5 million 2017 Note, net of debt issuance costs of $115 thousand and amortized the debt issuance costs over the life of the 2017 Note. For the year ended December 31, ~~2017,~~2018, the Company accrued ~~$136~~$257 thousand of interest expense and ~~$44~~$71 thousand in amortization of debt issuance costs related to the 2017 Note. For comparative purposes, an adjustment was made to separate the short-term debt balance and the 2017 Note derivative liability related to the value of certain conversion rights. Additionally, for comparative purposes, the 2017 interest accrual was shown separately from the change in accrued expenses in the Statement of Cash Flows in order to conform to 2018 presentation.

Due to the timing of the finalization of the 2017 Note financing in 2017, the 2017 Note was issued without stockholder approval. As a consequence, while the 2017 Note contains conversion provisions, the Purchaser had, for a period of time, no right to exercise those rights until such rights of exercise were approved by the stockholders of the Company. Stockholder approval of the Purchaser’s right to convert the 2017 Note was obtained at the Company’s Annual Meeting on May 24, 2018.

In December 2018, the maturity date of the 2017 Note was extended to March 31, 2019 in exchange for payment of $394 thousand which was the total interest accrued ~~interest~~for on the 2017 Note at December 31, 2018. Payment of this amount was made in January 2019. The modification extended the conversion rights and resulted in an additional $40 thousand of debt discount liability being recorded along with issuance costs of $53 thousand.

For the three and six months ended March 31, 2019, the Company accrued $62 thousand of interest expense and recorded an additional $40 thousand of interest expense related to the amortized derivative liability recorded for the 2017 Note. For the three months ended March 31,June 30, 2018, the Company ~~accrued~~recognized interest expense of ~~$62~~$63 and $124 thousand and amortization of debt issuance costs of ~~$18~~$19 and $37 thousand, respectively, related to the 2017 Note.

In March 2019, the maturity date of the 2017 Note was extended to May 1, 2019. The modification extended the beneficial conversion rights and resulted in an additional ~~$14 thousand of~~ debt discount liability, ~~being recorded.~~which was not recorded since it was determined to be immaterial to the consolidated financial statements. In April 2019, the maturity date of the 2017 Note was further extended to July 1, ~~2019.~~2019, which resulted in $24 thousand of debt discount liability being recorded. In June 2019, the maturity date of the 2017 Note was further extended to October 1, 2019, which resulted in an additional $31 thousand of the debt discount liability being recorded. For the three and six months ended June 30, 2019, the Company recognized interest expense of $63 and $126 thousand related to the 2017 Note, as well as interest expense related to the additional debt discount liability of $55 thousand and $55 thousand, respectively.

On May 30, 2018, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $1.75 million (the “2018 Note”) with a maturity date of May 30, 2023. Interest accrued at an annually compounded rate of 10%. The Purchaser is a related party and is the Company’s largest ~~shareholder.~~

The 2018 Note accrues interest at a rate equal to 10% per annum, compounded annually, other than during the continuance of an event of default, when the 2018 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the maturity date, May 30, 2023.stockholder.

The entire outstanding principal balance under the 2018 Note and all unpaid accrued interest thereon iswas convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, at the option of the Purchaser at a conversion price of US$0.018 per CDI. InSubsequently, the ~~event that the Borrower issues~~Company issued additional CDIs in a subsequent equity financing in September 2018 at a price per CDI ~~that is less than~~of US$~~0.018,~~0.0144, resulting in an adjustment of the conversion price ~~of the 2018 Note will adjust~~ to the lower CDI conversion price. In addition, upon a change of control of the Company, the Purchaser may demand prepayment of accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance of the 2018 Note.

The 2018 Note contains customary events of default including a failure to perform obligations under the 2018 Note Purchase Agreement, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing

business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2018 Note may be accelerated. The 2018 Note Purchase Agreement and related 2018 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.US$0.0144 per CDI.

In connection with the issuance of the 2018 Note, the Company also issued to the Purchaser a warrant (the “2018 Warrant”) to purchase 97,222,200 CDIs (representing 1,944,444 common shares) at an initial exercise price of US$0.018 per CDI, as per the 2018 Note conversion price, the warrant exercise price was subsequently adjusted to US$0.0144 per CDI, and is subject to further exercise price adjustment on certain conditions as described in the ~~warrant, which warrant expires on May 30, 2023 (the “2018 Warrant”).~~2018 Warrant. The 2018 Warrant may be exercised at any time on a cash or cashless ~~basis. The 2018 Warrant includes a price protection clause. If the Company issues securities in a subsequent financing at a per CDI price of less than US$0.018, the exercise price of~~basis until the 2018 Warrant ~~will be reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold.~~expires on May 30, 2023.

The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, ASC 815-40 Contracts in an Entity's Own Equity and ASC 470-20 Debt with Conversion and Other Options to determine the appropriate classification of the 2018 Note and 2018 Warrant. ~~The~~On issuance, the 2018 Warrant was determined to be a freestanding instrument meeting the requirements for equity classification. Accordingly, the ~~relative~~ fair value estimated for the 2018 Warrant, totaling approximately $743 thousand, has been recorded as a discount to the debt with the offset to additional paid-in capital. The 2018 Note was also evaluated for beneficial conversion feature ("BCF") subsequent to the allocation of proceeds among the 2018 Note and 2018 Warrant. Based upon the effective conversion price of the 2018 Note after considering the stock price at the date of issuance and the allocation of estimated fair value to the 2018 Warrant, it was determined that the 2018 Note contained a BCF. The value of the BCF was computed to be approximately $1.2 million but has been capped at approximately $1.0 million so as to not exceed the total proceeds from the 2018 Note after deducting the value allocated to the 2018 Note and 2018 Warrant. The effective interest rate on the note after the discounts is 26.4%.

The Company recorded the 2018 Note at issuance, net of the total debt discount of $1.75 million and ~~will amortize~~amortized the debt discount over the life of the 2018 Note. For the three and six months ended ~~March 31,~~June 30, 2019, the Company accrued interest expense of $47 and $91 thousand and debt discount amortization of $74 and $146 thousand. For the three and six months ended June 30, 2018, the Company recognized interest expense of ~~$44~~$14 thousand and debt discount amortization of ~~$72 thousand.~~$25 thousand, and interest expense derived from issuance costs of $85 thousand, respectively.

The 2018 Note was converted on June 30, 2019 to 134,852,549 CDIs (representing 2,697,050 common shares). The principal of $1.75 million converted to 121,527,777 CDIs (representing 2,430,555 common shares) and the accrued interest of $192 thousand converted to 13,324,772 CDIs (representing 266,495 common shares). Upon the conversion of the 2018 Note, the Company also recorded $1.4 million of unamortized interest expense

related to the unamortized debt discount. As of June 30, 2019, the conversion of the CDIs had been executed, but not yet settled with the CDIs issued and available.

On March 15, 2019, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $1 million (the “March 2019 Note”). The Purchaser is a related party and is the Company’s largest ~~shareholder.~~

stockholder. Being a related party, certain conversion features in the March 2019 Note and the March 2019 warrant required stockholder approval, which was obtained on June 30, 2019. The March 2019 Note ~~accrues~~accrued interest at a rate equal to 10% per annum, compounded ~~annually, other than during the continuance of an event of default, when~~annually. The March 2019 Note was to mature on March 15, 2024. Issuance costs related to the March 2019 Note ~~accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the maturity date, March 15, 2024.~~were $50 thousand.

The entire outstanding principal balance under the March 2019 Note and all unpaid accrued interest thereon iswas convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, at the option of the Purchaser at a conversion price of US$0.0127 per CDI. In the event that the Borrower issues additional CDIs in a subsequent equity financing at a price per CDI that is less than US$0.0127, the conversion price of the March 2019 Note will adjust to the lower CDI conversion price. In addition, upon a change of control of the Company, the Purchaser may demand prepayment of accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance of the March 2019 Note.

The March 2019 Note contains customary events of default including a failure to perform obligations under the March 2019 Note Purchase Agreement, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the March 2019 Note may be accelerated. The March 2019 Note Purchase Agreement and related March 2019 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type.

In ~~connection~~conjunction with the issuance of the March 2019 Note, the Company ~~has, subject to obtaining shareholder approval, agreed to issue to the Purchaser~~issued a warrant (the “March 2019 Warrant”) to purchase 78,984,823 CDIs (representing 1,579,696 common shares) at an initial exercise price of US$0.0127 per CDI, subject to adjustment as described in the ~~warrant, which warrant expires on the fifth anniversary of the date of issuance (the “March~~March 2019 ~~Warrant”). Upon issuance, the~~Warrant. The March 2019 Warrant ~~may be exercised~~required the approval of stockholders and was recorded in derivative liability as it was not exercisable until approved on June 30, 2019. The warrant is exercisable at any time on a cash or cashless ~~basis.~~basis prior to its expiration on June 30, 2024. The March 2019 Warrant includes a price protection ~~clause. If~~clause such that if the Company issues securities in a subsequent financing at a per CDI price of less than US$0.0127, the exercise price of the March 2019 Warrant will be reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold.

Upon approval of the conversion features and issuance of the warrants on June 30, 2019, the Company remeasured the warrant liability and recorded a $576 thousand other expense to the consolidated statement of operations and then reclassified $1,447 thousand of fair value of warrants from derivative liability to equity as approval of the warrant made the warrant immediately exercisable. The Company ~~recorded~~then evaluated the March 2019 Note ~~net of~~for beneficial conversion feature ("BCF’). Based upon the ~~total debt discounts related to the warrants of $871 thousand and issuance costs of $50 thousand and will amortize the debt discount over the life~~effective conversion price of the March 2019 ~~Note.~~ Note after considering the stock price at the date of stockholder approval and the allocation of estimated fair value to the March 2019 Warrant, it was determined that the March 2019 Note contained a BCF. The value of the BCF was computed to be approximately $741 thousand but has been capped at approximately $265 thousand so as to not exceed the total proceeds from the March 2019 Note after deducting the value allocated to the March 2019 Note and 2019 Warrant. The relative fair value of the warrant upon stockholder approval was approximately $735 thousand. The total debt discount on the March 2019 Note upon stockholder approval was $1M.

The effective interest rate on the ~~2019 note~~Note after the discounts is 29.4%. For the three and six months ended June 30, 2019, immediately prior to the Note conversion the Company recognized accrued interest expense of $25 and $29 thousand and debt discount amortized to interest expense of $52 and $60 thousand, respectively.

On Note conversion, unamortized debt discount of $1 million was recorded as interest expense. The March 2019 Note principal of $1 million and accrued interest of $30 thousand were transferred to common stock subscribed but unissued. The conversion features of the March 2019 Note were approved on June 30, 2019 and on the same day, the March 2019 Note was converted to 81,070,003 CDIs (representing 1,621,400 common shares). The principal of $1 million converted to 78,740,157 CDIs (representing 1,574,803 common shares) and the accrued interest of approximately $30 thousand converted to 2,329,846 CDIs (representing 46,596 common shares).

On May 8, 2019, the Company entered into a Note Purchase Agreement by and between the Company, as borrower, and Crystal Amber Fund Limited, as purchaser (the “Purchaser”). Pursuant to the Note Purchase Agreement, the Company issued and sold to the Purchaser a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $3 million (the “May 2019 Note”). The Purchaser is a related party and is the Company’s largest stockholder. Being a related party, certain conversion features in the May 2019 Note and the May 2019 warrant required stockholder approval, which was obtained on June 30, 2019.

The May 2019 Note was funded in four tranches, starting on May 8, 2019 and the full $3 million funding was completed on June 28, 2018. The note accrued interest at 10% per annum, computed on the daily funded balance until completion of funding on June 28, 2019, when interest began to compound annually. The May 2019 Note was to mature on May 8, 2024. Issuance costs were $87 thousand.

The entire outstanding principal balance under the May 2019 Note and all unpaid accrued interest thereon was convertible into CHESS Depositary Interests (“CDIs”), each representing 1/50th of a share of the Company’s common stock, at the option of the Purchaser at a conversion price of US$0.0127 per CDI.

In conjunction with the issuance of the May 2019 note, the Company issued a warrant (the “May 2019 Warrant”) to purchase 236,220,472 CDIs (representing 4,724,409 common shares) at an initial exercise price of US$0.0127 per CDI, subject to adjustment as described in the May 2019 Warrant. The May 2019 Warrant required the approval of stockholders and was recorded in derivative liability as it was not exercisable until approved on June 30, 2019. The warrant is exercisable at any time on a cash or cashless basis, prior to its expiration on June 30, 2024. The May 2019 Warrant includes a price

~~In May 2019,~~protection clause such that if the Company ~~completed~~issues securities in a ~~Convertible Term Promissory Note (the “May 2019 Note”) and Warrant (the “May 2019 Warrant”)~~subsequent financing ~~with its largest shareholder, Crystal Amber, for~~at a ~~gross amount~~per CDI price of ~~up to $3.0 million. The May 2019 Note accrues interest at 10% per annum, computed daily until~~less than US$0.0127, the ~~date upon which full funding under~~exercise price of the May 2019 Note is anticipated to be received, regardless of whether full funding is made on such date (the “Full Funding Date”) and compounded annually beginning on the Full Funding Date. The $3.0 million paymentWarrant will be ~~made~~reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold.

The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, ASC 815-40 Contracts in ~~several tranches. Certain specific terms associated~~an Entity's Own Equity and ASC 470-20 Debt with Conversion and Other Options to determine the ~~conversion~~appropriate classification of the May 2019 Note and May 2019 Warrant. On issuance, the May 2019 Warrant was determined to be a freestanding instrument meeting the requirements for liability classification due to not having stockholder approval. Accordingly, the fair value estimated for the May 2019 Warrant, totaling approximately $3.2 million, was recorded as a discount to the debt with the offset to derivative liabilities.

Upon approval of the conversion features and issuance of the warrants on June 30, 2019, the Company revalued the warrant liability and recorded a remeasurement of derivative liabilities in the amount of $1.14 million to the consolidated statements of operations and then reclassified $4,337 thousand of fair value of warrants from derivative liability to equity as approval of the warrant which made the warrant immediately exercisable. The Company then evaluated the May 2019 Note for beneficial conversion feature ("BCF’). Based upon the effective conversion price of the May 2019 ~~Warrant require shareholder~~Note after considering the stock price at the date of stockholder approval ~~which will be sought in a vote~~and the allocation of ~~the stockholders of the Company during the Annual Meeting of Stockholders anticipated~~estimated fair value to ~~be held in May or June 2019. The May 2019 Note matures and~~ the May 2019 Warrant, ~~if issued, will expire~~it was determined that the May 2019 Note contained a BCF. The value of the BCF was computed to be approximately $2.0 million but has been capped at approximately $844 thousand so as to not exceed the total proceeds from the May 2019 Note after deducting the value allocated to the May 2019 Note and May 2019 Warrant. The relative fair value of the warrant upon shareholder approval was approximately $2,136 thousand. The total debt discount on the ~~fifth anniversary~~May 2019 note upon shareholder approval was $3 million.

The effective interest rate on the Note after the discounts is 29.4%. For the three and six months ended June 30, 2019, immediately prior to the Note conversion the Company recognized accrued interest expense of $19 thousand and debt discount amortized to interest expense of $180 thousand, respectively.

On Note conversion, unamortized debt discount of $3 million was reclassed to interest expense. The March 2019 Note principal of $3 million and accrued interest of $19 thousand were transferred to common stock subscribed but unissued. The conversion features of the ~~Full Funding Date. Crystal Amber is deemed a Related Party~~May 2019 Note were approved on June 30, 2019 and on the same day, the May 2019 Note was converted to 237,687,411 CDIs (representing 4,753,747 common shares). The principal of $3 million converted to 236,220,472 CDIs (representing 4,724,409 common shares) and the accrued interest of $19 thousand converted to 1,466,939 CDIs (representing 29,338 common shares).

On January 1, 2019, the Company ~~for ASX purposes due~~adopted Topic 842 using the modified retrospective approach. There was no impact to retained earnings upon adoption of Topic 842 as there were no active long-term leases in place at the ~~size~~adoption date. Leases with an initial term of ~~its ownership position.~~

~~Lease Commitments~~12 months or less are not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases).

In June 2016, the Company entered into a non-cancelable agreement to lease approximately 4,200 square feet of office space in Boston, Massachusetts. The lease commenced in June 2016 and expired in April 2018. Rent during the term was $12 thousand per month.

In December 2018, the Company entered into a 6-month membership agreement with WeWork for 985 square feet of office space located in Boston, Massachusetts. The committed lease term ~~expires~~expired in May 2019 and ~~contains~~contained a two-month cancellation provision.

~~Future minimum lease payments under all short-term lease arrangements at March 31, 2019 are $36 thousand.~~

~~Rent expense on non-cancelable operating leases was approximately $56 and $37 thousand for the three months ended March 31, 2019 and 2018, respectively.~~ The WeWork agreement contained no explicit or guaranteed extension provisions.

On ~~May 1,~~April 22, 2019, the Company entered into a ~~right of use~~Right-of-Use lease ~~commencing May 1, 2019~~ for 3,520 square feet of office space in Boston, Massachusetts. The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. The lease has defined escalating rent payments and contains no extension or expansion rights. On lease execution, the Company ~~will record a fair~~recorded the approximately $509 thousand present value ~~right to use asset~~of the lease liability in short-term and long-term liabilities and recorded a related ~~operating~~Right of Use Asset. The Right-of-Use asset will be amortized to lease ~~liability of $643 thousand, the asset to be depreciated~~expense and the liability towill be ~~amortized~~reduced by the rent payments over the term of the lease. As of June 30, 2019, the accumulated depreciation on the lease was approximately $11 thousand. Additional ~~pro-rata building operating expenses,~~ property ~~taxes~~tax allocations and separately metered utilities will all be expensed in the period ~~incurred~~incurred.

The Company's leases generally do not provide an implicit rate and therefore the Company used 10% as an estimate of its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company had no leases currently classified as finance leases or previously classified as capital leases in either reporting period.

The following table presents supplemental balance sheet information related to our operating lease:

The total operating lease cost for short-term leases not included as lease liabilities and right of use assets on the balance sheet was $55 thousand and $92 thousand for the three-month and six-month periods ended June 30, 2019, respectively. The total operating lease cost for long-term leases included as lease liabilities and right of use assets on the balance sheet was $16 thousand for the three-month and six-month periods ended June 30, 2019.

The maturity of the Company’s finance and operating lease liabilities as of June 30, 2019 are as follows:

On May 22, 2017, the ~~Stockholders~~stockholders of the Company approved an increase of its authorized shares of Common Stock from 13,000,000 to 50,000,000 and to eliminate Class B shares of Common Stock of the Company. As of ~~March 31,~~June 30, 2019, the authorized capital stock of the Company consists of 50,500,000 shares, of which 50,000,000 shares are designated as Common Stock and 500,000 shares are designated as Preferred Stock.

In 2018, the Company received commitments for two private placements to sophisticated and professional investors in Australia, the United States and the United Kingdom, consisting of U.S. and non-U.S. persons (as defined in Regulation S (“Regulation S”) of the Securities Act of 1933 (the “Securities Act”)) to raise up to approximately $6.61 million (the “2018 Placements”). The first placement (“First Quarter 2018 Placement”) consisted of a total of 406,002,869 fully paid CDIs of the Company (representing 8,120,057 shares of common stock) at an issue price of A$0.035 per CDI. The issue of CDIs under the First Quarter 2018 Placement occurred in two tranches. The first tranche closed on January 22, 2018 (US Eastern time), pursuant to which the Company issued 28,467,063 CDIs (representing 569,341 shares of common stock) resulting in gross proceeds of approximately $781 thousand and related issuance costs of $63 thousand. The closing of the second tranche of the First Quarter 2018 Placement resulted in ~~the raising~~gross proceeds of $824 thousand and related issuance costs of $39 thousand by the issue of 30,313,556 CDIs (606,271 shares) following stockholder approval granted on February 27, 2018. There were two participants in the First Quarter 2018 Placement second tranche; Crystal Amber Fund, a related party, purchased 27,391,756 CDIs. A Board member of the Company purchased 2,921,800 CDIs.

The second placement (“Autumn 2018 Placement”) consisted of a total of 347,222,250 fully paid CDIs of the Company (representing 6,944,445 shares of common stock) at an issue price of A$0.020 per CDI. The investors in the Autumn 2018 Placement included certain existing investors. The issue of these CDIs occurred in two tranches. The first tranche closed on September 20, 2018 (US Eastern time), pursuant to which the Company issued 150,000,000 CDIs (representing 3,000,000 shares of common stock) resulting in gross proceeds of approximately $2.2 million and related issuance costs of $56 thousand. The closing of the second tranche resulted in ~~the raising~~gross proceeds of $2.8 million by the issue of 197,222,250 CDIs (representing 3,944,445 shares of common stock) following stockholder approval at the adjourned Special Meeting of stockholders on October 29, 2018. There were three participants in the second tranche; Crystal Amber Fund, a related party, purchased 168,194,450 CDIs. Existing investors in the United States and Australia also purchased 23,819,450 and 5,208,350 CDIs, respectively. All second tranche CDIs were allotted to investors in November 2018.

On June 30, 2019, Crystal Amber converted the 2018 Note to 134,852,549 CDIs (representing 2,697,050 common shares). The principal of $1.75 million converted to 121,527,778 CDIs (representing 2,430,555 common shares) and the accrued interest of $192 thousand converted to 13,324,772 CDIs (representing 266,495 common shares).

On June 30, 2019, Crystal Amber converted the March 2019 Note to 81,070,003 CDIs (representing 1,621,400 common shares). The principal of $1 million converted to 78,740,157 CDIs (representing 1,574,803 common shares) and the accrued interest of approximately $30 thousand converted to 2,329,846 CDIs (representing 46,596 common shares).

On June 30, 2019, Crystal Amber converted the May 2019 Note to 237,687,411 CDIs (representing 4,753,747 common shares). The principal of $3 million converted to 236,220,472 CDIs (representing 4,724,409 common shares) and the accrued interest of approximately $19 thousand converted to 1,466,939 CDIs (representing 29,338 common shares).

The Company has two stock-based compensation plans. In May 2003, the Board of Directors adopted the 2003 Omnibus Stock Plan (the “2003 Plan”), which provides for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants to purchase up to an aggregate of 922,086 shares of the Company’s common stock.

In August 2011, the Board of Directors adopted the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”, together with the 2003 Plan, the “Plans”) as the successor to the 2003 Plan. Under the 2011 Plan, the Company may grant incentive stock options, nonqualified stock options, restricted and unrestricted stock awards and other stock-based awards. The Company had initially reserved 450,000 shares of its common stock for issue under the 2011 Plan. Awards that are returned to the Company’s 2003 Plan as a result of their forfeiture, expiration or cancellation without delivery of common stock shares or that result in the forfeiture of shares back to the Company on or after August 1, 2011, the date the 2011 Plan became

effective, are automatically made available for issuance under the 2011 Plan. At August 1, 2011, 80,235 shares available for grant under the 2003 Plan were transferred to the 2011 Plan. At ~~March 31,~~June 30, 2019, there were 1,748,812 shares available for future grant under the 2011 Plan.

In addition, the 2011 Plan allows for an annual increase in the number of shares available for issue under the 2011 Plan commencing on the first day of each fiscal year during the period beginning in fiscal year 2012 and ending in fiscal year 2020. The annual increase in the number of shares shall be equal to the lowest of:

Accordingly, in the first quarter of fiscal 2019, 500,000 options available for future grant were added to the 2011 Plan.

Stock-based compensation is reflected in the consolidated statements of operations as follows for the three and six months ended ~~March 31,~~June 30, 2019 and 2018 (in thousands):

	Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018		2019		2018
Research and development	$	16	$	5	$	16	$	—	$	32	$	5
Sales and marketing		—		6		—		4		—		10
General and administrative		42		18		41		31		84		49
	$	58	$	29	$	57	$	35	$	116	$	64

The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant. From time to time, the Company grants stock options to purchase common stock subject to performance-based milestones. The vesting of these stock options will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective stock option over the implicit service period.

In calculating stock-based compensation costs, the Company estimates the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of short-lived, exchange-traded options that have no vesting restrictions and are fully transferable. Such costs are then recognized over the requisite service period of the awards on a straight-line basis.

Determining the fair value of stock-based awards using the Black-Scholes option-pricing model requires the use of highly subjective assumptions, including the expected term of the award and expected stock price volatility. The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three and six months ended ~~March 31,~~June 30, 2019 and 2018:

	Three Months Ended March 31,						Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018			2019			2018
Expected volatility		122.0	%		114.9	%		126.1	%		119.4	%		126.1	%		117.1	%
Expected term (in years)		6.05			6.05			6.05			6.05			6.05			6.05
Risk-free interest rate		2.3	%		2.6	%		1.8	%		2.6	%		1.8	%		2.5	%
Expected dividend yield		0	%		0	%		0	%		0	%		0	%		0	%

The following table summarizes share-based activity under the Company’s stock option plans for the ~~three~~six months ended ~~March 31,~~June 30, 2019:

	Shares of Common Stock Attributable to Options		Weighted- Average Exercise Price		Weighted- Average Contractual Life		Aggregate Intrinsic Value		Shares of Common Stock Attributable to Options		Weighted- Average Exercise Price		Weighted- Average Contractual Life		Aggregate Intrinsic Value
					(in years)		(in thousands)						(in years)		(in thousands)
Outstanding at December 31, 2018		985,224	$	2.24	8.48		$	—		985,224	$	2.24	8.48		$	—
Granted		160,000					$	—		235,000					$	—
Exercised		—					$	—		—					$	—
Cancelled		—					$	—		—		—		—	$	—
Outstanding at March 31, 2019		1,145,224	$	2.24		8.24	$	1
Vested or expected to vest at March 31, 2019		1,145,224	$	2.24		8.24	$	1
Exercisable at March 31, 2019		451,805	$	4.87		6.87	$	—
Outstanding at June 30, 2019										1,220,224	$	2.24		8.24	$	1
Vested or expected to vest at June 30, 2019										1,220,224	$	2.24		8.24	$	1
Exercisable at June 30, 2019										486,916	$	4.87		6.87	$	—

As of ~~March 31,~~June 30, 2019, there was approximately ~~$637~~$586 thousand of unrecognized stock-based compensation related to unvested stock option grants having service-based vesting under the Plans which is expected to be recognized over a weighted-average period of 2.3 years. The intrinsic value in the table above represents the difference between the fair value of the Company’s common stock on the measurement date and the exercise price of the stock option.

The stock-based compensation plans provide that grantees may have the right to exercise an option prior to vesting. Shares purchased upon the exercise of unvested options will be subject to the same vesting schedule as the underlying options and are subject to repurchase at the original exercise price by the Company should the grantee discontinue providing services to the Company for any reason, prior to becoming fully vested in such shares.

Each restricted stock unit and performance stock unit (“RSU & PSU”) issued under the Company Plans represents a contingent right to receive one share of the Company’s common stock. The RSUs & PSUs outstanding at ~~March 31,~~June 30, 2019 vest upon the achievement of certain product revenue, regulatory and reimbursement milestones. There is no consideration payable on the vesting of RSUs & PSUs issued. Upon vesting, RSUs and PSUs are exercised automatically and settled in shares of the Company’s common stock.

The following table summarizes information related to RSU & PSU activity for the ~~three~~six months ended ~~March 31,~~June 30, 2019:

	Number of Units		Weighted- Average Contractual Life		Aggregate Intrinsic Value		Number of Units		Weighted- Average Contractual Life		Aggregate Intrinsic Value
			(in years)		(in thousands)				(in years)		(in thousands)
Outstanding at December 31, 2018		250,000		7.23	$	141		250,000		7.23	$	141
Granted	—						—
Exercised	—						—
Cancelled	—						—		—		—
Outstanding at March 31, 2019		250,000		6.98	$	186
Outstanding at June 30, 2019								250,000		6.98	$	186

The aggregate intrinsic value at ~~March 31,~~June 30, 2019 and December 31, 2018 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of RSUs and PSUs outstanding. The fair value of each RSU and PSU award equals the closing price of the Company’s common stock on the date of ~~grant~~grant.

At ~~March 31,~~June 30, 2019, all RSUs and PSUs outstanding are subject to performance-based vesting criteria as described in the applicable award agreement. For these awards, vesting will occur upon the achievement of certain product revenue, regulatory and reimbursement milestones. When achievement of the milestone is deemed probable, the Company expenses the compensation of the respective stock award over the implicit service period.

At ~~March 31,~~June 30, 2019 and 2018, no RSUs and PSUs that have performance-based vesting criteria are considered probable of achievement. For the three and six months ended ~~March 31,~~June 30, 2019 and 2018, the Company did not recognize any stock-based compensation for RSUs and PSUs subject to performance-based vesting criteria.

As of ~~March 31,~~June 30, 2019, there remains approximately ~~$140~~$283 thousand of unrecognized stock-based compensation.

Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity.

The Company has historically reported various geographic segments, but at ~~March 31,~~June 30, 2019, the right-of-use-asset of approximately $487 thousand and all long-lived assets, comprised of property and equipment, of approximately ~~$60~~$51 thousand are all held in the U.S. and the Company did not have revenue for the three and six months ended ~~March 31,~~June 30, 2019 and 2018, respectively.

The Company did not recognize any revenue for the three and six months ended ~~March 31,~~June 30, 2019 and 2018, respectively.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2018 included in our Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements that involve significant risks, uncertainties and assumptions. As a result of many factors, such as those set forth under “Risk Factors” Item 1A. of our Annual Report on Form 10-K, which are incorporated herein by reference, our actual results may differ materially from the results described in or implied by the ~~forward- looking~~forward-looking statements described in the following discussion and analysis.

We are a clinical stage medical device company located in Boston, Massachusetts. We have developed EndoBarrier, a medical device intended for treatment of patients with type 2 diabetes and obesity, and we are taking the steps necessary to obtain the regulatory approvals required to market this product. In order to market EndoBarrier in the U.S., we must obtain approval from the FDA. In order to market EndoBarrier outside of the U.S., we are required to comply with various regulations imposed by the countries in which we seek to sell the product.

In 2010, EndoBarrier received CE Marking for sale in the European Union and in 2011, EndoBarrier was listed on the Australian Register of Therapeutic Goods. As a result, during 2013 and 2014, we received approximately $2.8 million and $2.25 million in revenue from the sale of EndoBarrier in Europe, South America and the Asia Pacific region. In the U.S. in 2013, we began enrollment of patients in the initial pivotal trial of EndoBarrier, which we refer to as the ENDO Trial.

In the third quarter of 2015, we announced our decision to discontinue the ENDO Trial because patients were experiencing a higher than previously observed level of hepatic (liver) abscesses. In the fourth quarter of 2016, we received formal notification from the Therapeutic Goods Administration of the Australian government of the cancellation of EndoBarrier’s inclusion on the Australian Register of Therapeutic Goods. In the fourth quarter of 2017 we received formal notification of CE mark withdrawal from our notified body in Europe, preventing the sale of EndoBarrier in Europe and select Middle Eastern countries. We undertook comprehensive cost-cutting measures throughout 2015 and 2016, including significantly reducing the number of our employees.

Following our decision to discontinue the ENDO Trial, we undertook significant investigational and scientific analysis with the goal of reducing the incidence rate and severity of hepatic abscess that present concurrently with the EndoBarrier treatment. This investigational work focused on understanding the root cause of hepatic abscess and how to reduce the rate of occurrence. This included: DNA analysis of normal EndoBarrier removals as well as hepatic abscess EndoBarrier removals, numerous meta-analyses and responder cohort analyses, investigation into the contributing factors represented by proton pump inhibitors (PPIs), leaky gut syndrome and microbiome analyses, among other research. This allowed the company to modify the medications utilized with EndoBarrier, most notably discontinuation of chronic double-dose PPI usage during EndoBarrier implant.

In July 2018, we submitted to the FDA an application for investigational device exemption, or IDE, to commence a new pivotal trial evaluating the safety and efficacy of EndoBarrier in the United States pending Institutional Review Board, or IRB, approval. In August 2018, we received approval of an IDE from the FDA to begin enrollment in this pivotal trial, and IRB approval was granted in February 2019. In this report, we refer to this pivotal trial as the GID ~~18-1~~STEP-1 clinical trial.

For financial reporting purposes, we have one reportable segment, which designs, manufactures and plans to market EndoBarrier.

To date, we have devoted substantially all our efforts to research and development, business planning, clinical research, clinical study management, reimbursement development, product commercialization, acquiring operating assets and raising capital. We have incurred significant operating losses since our inception in 2003. As of ~~March 31,~~June 30, 2019, we had an accumulated deficit of approximately ~~$270~~$279 million. We expect to incur net losses for the next several years while we continue to evaluate which markets are appropriate to continue pursuing regulatory approval, reimbursement, market awareness and general market development efforts, and continue to restructure our business and costs, establish new priorities, continue limited research, and evaluate strategic options.

To date, the Company has raised net proceeds of approximately ~~$270~~$273 million through the issuance of convertible debt and sales of our equity. See Note 1 of the Consolidated Financial Statements (Nature of Business — Financing History) for a detailed description of the Company’s financing history.

Our corporate headquarters are in Boston, Massachusetts. The Company ~~has~~ executed a three-year lease commencing May 1, 2019, allowing us to terminate the Company’s ~~existing~~former short-term lease and exit our ~~current~~former office space as of May 31, 2019.

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that may affect the reported amounts of assets and liabilities, and the reported amounts of revenues and expenses during the reported periods and related disclosures. These estimates and assumptions, including those related to income taxes including the valuation allowance for deferred tax assets, research and development expenses, contingencies, stock-based compensation, going concern considerations, lease liabilities and derivative valuations are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on our historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from our estimates under different assumptions or conditions. See Note 2 of the Consolidated Financial Statements (Summary of Significant Accounting Policies and Basis of Presentation — New Accounting Pronouncements) for a detailed discussion of new accounting pronouncements, their adoption by the Company, and their impact (if any) on the Company’s financial statements.

The following is a description of significant components of our operations, including significant trends and uncertainties that we believe are important to an understanding of our business and results of operations (in thousands).

	Three Months Ended March 31,						Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018			2019			2018
	(in thousands)						(in thousands)
Operating expenses:
Research and development		810			373		$	810		$	254		$	1,620		$	627
Sales and marketing		16			204			6			312			22			516
General and administrative		1,344			1,185			1,393			855			2,737			2,040
Total operating expenses		2,170			1,762			2,209			1,421			4,379			3,183
Loss from operations		(2,170	)		(1,762	)		(2,209	)		(1,421	)		(4,379	)		(3,183	)
Other income (expense):
Interest income		3			7			—			9			3			16
Interest expense		(177	)		(81	)		(5,912	)		(207	)		(6,089	)		(288	)
Foreign exchange gain (loss)		(9	)		9			15			(2	)		6			8
Gain on write-off of accounts payable		29			—			61			—			90			—
Re-measurement of derivative liabilities		(1	)		1			(1,687	)		2			(1,688	)		3
Other income (expense), net		(155	)		(64	)		(7,523	)		(198	)		(7,678	)		(261	)
Loss before income tax expense		(2,325	)		(1,826	)		(9,732	)		(1,619	)		(12,057	)		(3,444	)
(Benefit from) Provision for income taxes		6			(18	)		26			15			32			(3	)
Net loss	$	(2,331	)	$	(1,808	)	$	(9,758	)	$	(1,634	)	$	(12,089	)	$	(3,441	)

Basic and diluted net loss per common share		(0.12	)	$	(0.15	)		(0.51	)	$	(0.13	)		(0.63	)	$	(0.29	)
Weighted-average number of common shares used in basic and diluted net loss per common share		19,277,545			11,803,221			19,277,545			12,333,101			19,277,545			12,069,624

Three and six months ended ~~March 31,~~June 30, 2019 compared to three and six months ended ~~March 31,~~June 30, 2018

Revenue. The Company did not record any revenues or associated cost of revenue during the three and six months ended ~~March 31,~~June 30, 2019 and 2018, respectively.

	Three Months Ended										Three Months Ended										Six Months Ended
	March 31,				Change						June 30,				Change						June 30,				Change
	2019		2018		$			%			2019		2018		$			%			2019		2018		$			%
	(dollars in thousands)										(dollars in thousands)										(dollars in thousands)
Research and development	$	810	$	373	$	437			117.2	%	$	810	$	254	$	556			218.9	%	$	1,620	$	627	$	993			158.4	%
Sales and marketing		16		204		(188	)		(92.2	)%		6		312		(306	)		(98.1	)%		22		516		(494	)		(95.7	)%
General and administrative		1,344		1,185		159			13.4	%		1,393		855		538			62.9	%		2,737		2,040		697			34.2	%
Total operating expenses	$	2,170	$	1,762	$	408			23.2	%	$	2,209	$	1,421	$	788			55.5	%	$	4,379	$	3,183	$	1,196			37.6	%

Research and Development Expense. The increase in research and development expense for the three and six months ended ~~March 31,~~June 30, 2019 compared to the three and six months ended ~~March 31,~~June 30, 2018 was primarily due to an increase in salary and employee-related costs caused by increased headcount and increased consulting fees. The Company has been accelerating its efforts to prepare for the ~~GID 18-1~~STEP-1 clinical ~~trial.~~trial, which is expected to begin in Q3 2019.

Sales and Marketing Expense. The decrease in sales and marketing expense for the three and six months ended ~~March 31,~~June 30, 2019 compared to the three and six months ended ~~March 31,~~June 30, 2018 was primarily due to a decrease in overall sales and marketing activities and a reclassification of existing overseas employee efforts to research and development.

General and Administrative Expense. The increase in general and administrative expense for the three and six months ended ~~March 31,~~June 30, 2019 compared to the three and six months ended ~~March 31,~~June 30, 2018 was primarily a result of market research costs including a health economics analysis and a research summary provided to potential ~~investors.~~investors, increased professional fees including corporate legal and costs related to being a public company and increased facilities costs.

We continue to look for ways to realize a more efficient cost structure in order to extend our cash runway. We may not be able to achieve cost reductions in all instances as we look to prepare to initiate clinical development in support of eventual commercial regulatory approval. We ~~expected~~ expect

operating expenses for the ~~first~~third quarter of 2019 to approximate those of the ~~fourth quarter of 2018. We expect operating expenses for the~~ second quarter of 2019 as we continue to ~~be substantially higher than those~~prepare for commencement of the ~~first quarter of 2019 predominantly due to expenses related to the initiation of the GID 18-1~~STEP-1 clinical trial.

	Three Months Ended												Three Months Ended												Six Months Ended
	March 31,						Change						June 30,						Change						June 30,						Change
	2019			2018			$			%			2019			2018			$			%			2019			2018			$			%
	(dollars in thousands)												(dollars in thousands)												(dollars in thousands)
Other income (expense):
Interest income	$	3		$	7		$	(4	)		(57.1	)%	$	—		$	9		$	(9	)		(100.0	)%	$	3		$	16		$	(13	)		(81.3	)%
Interest expense		(177	)		(81	)		(96	)		118.5	%		(5,912	)		(207	)		(5,705	)		2,756.0	%		(6,089	)		(288	)		(5,801	)		2,014.2	%
Foreign exchange gain (loss)		(9	)		9			(18	)		(200.0	)%		15			(2	)		17			(850.0	)%		6			8			(2	)		(25.0	)%
Gain on write-off of accounts payable		29			—			29			0.0	%		61			—			61			(—	)%		90			—			90			(—	)%
Re-measurement of derivative liabilities		(1	)		1			(2	)		(200.0	)%		(1,687	)		2			(1,689	)		(84,450.0	)%		(1,688	)		3			(1,691	)		(56,366.7	)%
Total other income (expense), net	$	(155	)	$	(64	)	$	(91	)		142.2	%	$	(7,523	)	$	(198	)	$	(7,325	)		3,699.5	%	$	(7,678	)	$	(261	)	$	(7,417	)		2,841.8	%

Other income (expense). The change to other income (expense), net, for the three and six months ended ~~March 31,~~June 30, 2019 compared to the three and six months ended ~~March 31,~~June 30, 2018 is primarily due to ~~interest expense~~the change in fair value of derivative liabilities and the conversion of the 2018, March 2019 and May 2019 Notes Payable to Crystal Amber Fund Limited, a related ~~to the Company’s 2018 Convertible Note and Warrant Financing~~party, offset by a gain on the write-off of prior period accounts payable.

The Company has incurred losses since our inception in March 2003 and as of ~~March 31,~~June 30, 2019, we had an accumulated deficit of approximately ~~$270~~$279 million. We have financed our operations from a combination of sales of equity securities and issuances of convertible term notes. As of ~~March 31,~~June 30, 2019, we had approximately ~~$1.3~~$2.5 million of cash and cash equivalents.

In June 2017, the Company completed a Convertible Term Promissory Note (the “2017 Note”) secured financing with its largest ~~shareholder,~~stockholder, Crystal Amber Fund Limited (“Crystal Amber”), for a gross amount of $5.0 million. The 2017 Note accrues interest at 5% per annum compounded annually. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership position. The 2017 Note ~~was originally due on December 31, 2018 and~~ contains provisions for conversion during its term and is also subject to security arrangements in favor Crystal Amber (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

The 2017 Note accrues interest at a rate equal to 5% per annum, compounded annually, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on ~~the original maturity date,~~ December 31, 2018 but was extended to March 31, 2019 in December 2018 (in exchange for payment of $394 thousand, the total accrued interest on the 2017 Note at December 31, 2018) and further extended to May 1, 2019 in March 2019, ~~and~~ July 1, 2019 in April 2019 and October 1, 2019 in June 2019.

The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, Crystal Amber is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if Crystal Amber were the absolute owner thereof.

In May 2018, the Company completed a Convertible Term Promissory Note (the “2018 Note”) and Warrant (the “2018 Warrant”) financing with its largest ~~shareholder~~stockholder, Crystal Amber, for a gross amount of $1.75 million. The 2018 Note ~~accrues~~accrued interest at 10% per annum compounded ~~annually.~~annually and was converted into 134,852,549 CDIs (representing 2,697,050 common shares) on June 30, 2019. The ~~2018 Note matures and the~~ 2018 Warrant expires on May 30, 2023. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership position. (See Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In 2018, the Company received commitments for two private placements to sophisticated and professional investors in Australia, the United States and the United Kingdom, consisting of U.S. and non-U.S. persons (as defined in Regulation S (“Regulation S”) of the Securities Act of 1933 (the “Securities Act”)) to raise up to approximately $6.61 million (the “2018 Placements”). The first placement (“First Quarter 2018 Placement”) consisted of a total of 406,002,869 fully paid CDIs of the Company (representing 8,120,057 shares of common stock) at an issue price of A$0.035 per CDI. The issue of CDIs under the First Quarter 2018 Placement occurred in two tranches. The first tranche closed on January 22, 2018 (US Eastern time), pursuant to which the Company issued 28,467,063 CDIs (representing 569,341 shares of common stock) resulting in gross proceeds of approximately $781 thousand and related issuance costs of $63 thousand. The closing of the second tranche of the First Quarter 2018 Placement resulted in ~~the raising~~gross proceeds of $824 thousand and related issuance costs of $39 thousand by the issue of 30,313,556 CDIs (606,271 shares) following stockholder approval granted on February 27, 2018. There were two participants in the First Quarter 2018 Placement second tranche; Crystal Amber, a related party, purchased 27,391,756 CDIs. A Board member of the Company purchased 2,921,800 CDIs.

The second placement (“Autumn 2018 Placement”) consisted of a total of 347,222,250 fully paid CDIs of the Company (representing 6,944,445 shares of common stock) at an issue price of A$0.020 per CDI. The investors in the Autumn 2018 Placement included certain existing investors. The issue of these CDIs occurred in two tranches. The first tranche closed on September 20, 2018 (US Eastern time), pursuant to which the Company issued 150,000,000 CDIs (representing 3,000,000 shares of common stock) resulting in gross proceeds of approximately $2.2 million and related issuance costs of $56 thousand. The closing of the second tranche resulted in ~~the raising~~gross proceeds of $2.8 million by the issue of 197,222,250 CDIs (representing 3,944,445 shares of common stock) following stockholder approval at the adjourned Special Meeting of Stockholders on October 29, 2018. There were three participants in the second tranche; Crystal Amber, a related party, purchased 168,194,450 CDIs. Existing investors in the United States and Australia also purchased 23,819,450 and 5,208,350 CDIs, respectively. All second tranche CDIs were allotted to investors in November 2018.

In March 2019, the Company completed a Convertible Term Promissory Note (the “March 2019 Note”) and Warrant (the “March 2019 Warrant”) financing with its largest ~~shareholder,~~stockholder, Crystal Amber, for a gross amount of $1.0 million. The March 2019 Note ~~accrues~~accrued interest at 10% per annum compounded ~~annually. Certain specific terms associated with the conversion of the March~~annually and was converted on June 30, 2019 ~~Note and issuance of the~~into 81,070,003 CDIs (representing 1,621,400 common shares). The March 2019 Warrant require shareholder approval, which will be sought in a vote of the stockholders of the Company during the Annual Meeting of Stockholders anticipated to be held in May or June 2019. The March 2019 Note matures on March 15, 2024 and the March 2019 Warrant, if issued, will expire on ~~the fifth anniversary of the date of issuance.~~June 30, 2024. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership ~~position. (See~~position (see Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

In May 2019, the Company completed a Convertible Term Promissory Note (the “May 2019 Note”) and Warrant (the “May 2019 Warrant”) financing with its largest ~~shareholder,~~stockholder, Crystal Amber, for a gross amount of up to $3.0 million. The May 2019 Note ~~accrues~~accrued interest at 10% per annum, computed daily until the date upon which full funding under the May 2019 Note is anticipated to be received, regardless of whether full funding is made on such date (the “Full Funding Date”) and compounded annually beginning on the ~~Full Funding Date. The $3.0 million payment will be made in several tranches. Certain specific terms associated with the conversion~~daily funded balance until completion of ~~the May~~funding on June 28, 2019, ~~Note and issuance of the May 2019 Warrant require shareholder approval, which will be sought in a vote of the stockholders of the Company during the Annual Meeting of Stockholders anticipated~~when interest began to ~~be held in May or June 2019.~~compound annually at 10% per annum. The May 2019 Note ~~matures and the~~converted on June 30, 2019 into 237,687,411 CDIs (representing 4,753,747 common shares). The May 2019 Warrant ~~if issued,~~ will expire on ~~the fifth anniversary of the Full Funding Date.~~June 30, 2024. Crystal Amber is deemed a Related Party of the Company for ASX purposes due to the size of its ownership ~~position. (See~~position (see Note 10 of the Consolidated Financial Statements for a more complete description of the terms and conditions of the financing).

During the ~~three~~six months ended ~~March 31,~~June 30, 2019, our cash and cash equivalents balance decreased as a result of funds utilized to support our operations offset by proceeds from financing activities.

The following table sets forth the major sources and uses of cash for each of the periods set forth below:

	Three Months Ended March 31,						Six Months Ended June 30,
	2019			2018			2019			2018
	(in thousands)						(in thousands)
Net cash (used in) provided by:
Operating activities	$	(3,464	)	$	(1,974	)	$	(5,287	)	$	(3,542	)
Investing activities		(5	)		—			(5	)		—
Financing activities		897			1,503			3,913			3,168
Net increase (decrease) in cash and cash equivalents	$	(2,572	)	$	(471	)	$	(1,379	)	$	(374	)

The primary uses of cash used in operating activities for the ~~three~~six months ended ~~March 31,~~June 30, 2019 were:

The primary uses of cash used in operating activities for the ~~three~~six months ended ~~March 31,~~June 30, 2018 were:

~~Table~~a net negative adjustment to cash flow from changes in working capital of ~~Contents~~approximately $322 thousand resulting primarily from decreases in accounts payable and accrued expenses.

•

~~a net negative adjustment to cash flow from changes in working capital of approximately $0.2 million resulting primarily from decreases in accounts payable and accrued expenses.~~

Cash Flows From Investing Activities

Cash used in investing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2019 was approximately $5 thousand. No cash was used in investing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2018.

Cash Flows From Financing Activities

Cash provided by financing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2019 totaled approximately ~~$897 thousand~~$3.9 million and primarily resulted from proceeds received in March 2019 from the March 2019 Note and May and June 2019 from the May 2019 Note payable to a related party.

Cash provided by financing activities for the ~~three~~six months ended ~~March 31,~~June 30, 2018 totaled approximately ~~$1.5~~$3.2 million and primarily resulted from net proceeds received in May 2018 from the 2018 Note payable to a related party and net proceeds from our private placement of CDIs offset by related issuance costs.

Table of Contents

Funding Requirements

As of ~~March 31,~~June 30, 2019, ~~our~~the Company’s primary source of liquidity ~~was our~~is its cash and cash equivalents ~~balances of approximately $1.3 million. We have subsequently begun~~balances. The Company continues to ~~receive proceeds of approximately $3 million under the May 2019 Note.~~

evaluate which markets are appropriate to pursue regulatory approvals, continue pursuing reimbursement, market awareness and general market development and selling efforts. The Company continues to restructure its business and costs, establish new priorities, and evaluate strategic options. As a result, ~~of our focus on a new pivotal clinical trial~~if the Company remains in the United States, and due to the lack of regulatory approval in the EU and other jurisdictions, we are focused on the generation of clinical data and regulatory approvals and are not currently focused on revenue-generating operations. As a result, we expectbusiness, it expects to incur significant operating losses for the next several years. ~~We do not expect our current~~

The Company has incurred operating losses since inception and at June 30, 2019 had an accumulated deficit of approximately $279 million, a working capital deficit of approximately $3.8 million, cash ~~balances~~used in operating activities of approximately $5.3 million and cash and cash equivalents of approximately $2.5 million. Cash provided by these activities will be ~~sufficient~~used predominantly to ~~enable us to~~prepare for and conduct ~~an additional~~the Company’s clinical trial, which will result in ~~the U.S. for the purpose of seeking regulatory approval from the FDA.~~increased expenses. The Company does not expect its current cash balances will be sufficient to operate beyond the end of ~~August 2019, or beyond July 1, 2019 if the Company is required to make payment to Crystal Amber under the 2017 Note on the due date of July 1,~~September 2019. If the 2017 Note reaches maturity, the Company will be required either to renegotiate the due date of the loan or to potentially cease operations. Crystal Amber and the Company are in discussion to further extend the due date of the 2017 Note, but there can be no assurance that any extension will occur. If the Company is able to amend the terms of the 2017 Note, it believes its cash and cash equivalents will be sufficient to fund operations to the end of August 2019, or until the modified due date of the note. The Company will need to raise additional funds through any combination of collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources. Furthermore, if the Company raises insufficient funds and is required to make payment to Crystal Amber under the 2017 Note on its maturity date of October 1, 2019 the Company will be required either to renegotiate the maturity date of the loan or to potentially cease operations. The Company expects to discuss further extension of the maturity date of the 2017 Note with Crystal Amber, but there can be no assurance that any extension will occur.

Our forecast of the period of time through which our financial resources will be adequate to support our operations are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in the “Risk Factors” in Item 1A. of our Annual Report on Form 10-K, which is incorporated by reference herein. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Due to the numerous risks and uncertainties associated with securing regulatory approval for EndoBarrier, at this time we are unable to estimate precisely the amounts of capital outlays and operating expenditures necessary to complete the task of obtaining regulatory approval for EndoBarrier. Our funding requirements will depend on many factors, including, but not limited to, the following:

the rate of enrollment of patients in our clinical trial and the completion of our trial in a timely fashion;

the rate of progress and cost of our commercialization activities;

the expenses we may incur in marketing and selling EndoBarrier subject to future regulatory approvals;

the timing and decisions of payer organizations related to reimbursement;

the revenue generated by sales of EndoBarrier;

the product performance from a safety and efficacy standpoint in addressing diabetes and obesity;

the success of our investment in our manufacturing and supply chain infrastructure;

the time and costs involved in obtaining regulatory approvals for EndoBarrier in new markets;

the success of our research and development efforts;

the costs associated with any additional clinical trial(s) required in the U.S. and other countries on a case by case basis;

the ability to ship CE marked products;

the emergence of competing or complementary developments; and

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

~~Table of Contents~~

We will continue to manage our capital structure and to consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. Any such capital transactions may or may not be similar to transactions in which we have engaged in the past and the ownership interests of our existing stockholders may be materially diluted. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all. In addition, the Company could be required to cease operations if it is unable to raise capital when needed.

Off–Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements (as that term is defined in Item 303(a)(4)(ii) of Regulation S-K) or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our own performance and the performance of our subsidiaries.

Table of Contents

Contractual Obligations and Commitments

The disclosure of our contractual obligations and commitments is set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Contractual Obligations and Commitments” in our Annual Report on Form 10-K.

There have been no material changes from the contractual commitments and obligations previously disclosed in our Annual Report on Form 10-K.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements please refer to Note 2, “Summary of Significant Accounting Policies and Basis of Presentation,” to our consolidated financial statements included in this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We conduct business in foreign countries and our cash flows are exposed to market risk from changes in currency exchange and interest rates.

Interest Rate Sensitivity

Our cash and cash equivalents of approximately ~~$1.3~~$2.5 million at ~~March 31,~~June 30, 2019, consisted of cash and money market funds, all of which will be used for working capital purposes. We do not enter into investments for trading or speculative purposes. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the U.S. and Australia. Because of the short-term nature of our cash and cash equivalents, we do not believe that we have any material exposure to changes in their fair values as a result of changes in interest rates. The continuation of historically low interest rates in the U.S. will limit our earnings on investments held in U.S. dollars.

Foreign Currency Risk

We conduct business in foreign countries. For U.S. reporting purposes, we translate all assets and liabilities of our non-U.S. entities at the period-end exchange rate and revenue and expenses at the average exchange rates in effect during the periods. The net effect of these translation adjustments is shown in the accompanying consolidated financial statements as a component of net loss.

Fluctuations in the exchange rate of the U.S. dollar against major foreign currencies, including the euro, British Pound and Australian dollar, can result in foreign currency exchange gains and losses that may significantly impact our financial results. These foreign currency transaction and translation gains and losses are presented as a separate line item in our consolidated statements of operations. Continued fluctuation of these exchange rates could result in financial results that are not comparable from quarter to quarter. We do not currently utilize foreign currency contracts to mitigate the gains and losses generated by the re- measurement of non- functional currency assets and liabilities but do hold cash reserves in currencies in which those reserves are anticipated to be expended.

All proceeds from our 2011, 2013, 2014, and 2016 offerings, along with a portion of our 2017 and 2018 offerings, were denominated in Australian dollars and as of ~~March 31,~~June 30, 2019, we held the equivalent of approximately US ~~$22~~$5 thousand denominated in Australian dollars and approximately US $1 thousand denominated in euros. Accordingly, we have had and will continue to have exposure to foreign currency exchange rate fluctuations. A change of 10% or more in foreign currency exchange rates of the Australian dollar or the euro would not have a material impact on our financial position and results of operations.

Effects of Inflation

We do not believe that inflation and changing prices over the three and six months ended ~~March 31,~~June 30, 2019 and 2018 had a significant impact on our results of operations.

~~Table of Contents~~

Item 4. ~~Control~~sControls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, or the Exchange Act, our management, including our principal executive officer and our principal financial and accounting officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and such information required to be disclosed by us in the reports we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Our principal executive officer and principal financial and accounting officer have concluded that, based on and as of the time of such evaluation, our disclosure controls and procedures were effective at the reasonable assurance level.

Table of Contents

Changes in Internal Control

As required by Rule 13a-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the internal control over financial reporting and concluded that there have not been any changes during the quarter ended ~~March 31,~~June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Controls and Procedures

Our management, including our principal executive officer and principal financial and accounting officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Thus, misstatements due to error or fraud may occur and not be detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of controls.

2628

Table of Contents

PART II – OTHER INFORMATION

Item 1A. Risk Factors:

In addition to the other information contained elsewhere in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks that we do not presently know or that we currently believe are immaterial could also materially and adversely affect any of our business, financial condition or future results. The trading price of our CDIs may decline due to these risks.

Item 2. Unregistered Sales of Equity Securities:

On May 30, 2018, the Company entered into a convertible note and warrant financing with its major shareholder, Crystal Amber Fund Limited (“Crystal Amber”), in which the Company issued to Crystal Amber a Senior Unsecured Convertible Promissory Note in the aggregate principal amount of $1.75 million (the “2018 Note”). In connectionOther than as previously disclosed on our Current Reports on Form 8-K filed with the ~~issuance of~~SEC, we did not issue any unregistered equity securities during the 2018 Note, the Company also issued to Crystal Amber a warrant to purchase 97,222,200 CDIs at an initial exercise price of $0.018 per CDI, subject to adjustment as described in the warrant, which warrant expires on Maythree months ended June 30, 2023 (the “2018 Warrant”). The 2018 Warrant may be exercised at any time on a cash or cashless basis. If the Company issues securities in a subsequent financing at a per CDI price of less than $0.018, the exercise price of the 2018 Warrant will be reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold. The 2018 Warrant was issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.2019.

In September 2018, the Company received commitments for a private placement of 347,222,250 fully paid CDIs of the Company (representing 6,944,445 shares of common stock) at an issue price of A$0.020 per CDI to sophisticated and professional investors, including certain existing investors in Australia, the United States and the United Kingdom consisting of U.S. and non-U.S. persons (as defined in Regulation S (“Regulation S”) of the Securities Act of 1933, as amended (the “Securities Act”)). The issue of these CDIs under this placement occurred in two tranches. The first tranche closed on September 20, 2018 (US Eastern time), pursuant to which the Company issued 150,000,000 CDIs (representing 3,000,000 shares of common stock) resulting in gross proceeds of approximately $2.2 million. The closing of the second tranche resulted in the raising of $2.8 million by the issue of 197,222,250 CDIs (representing 3,944,445 shares of common stock) following stockholder approval at the adjourned Special Meeting of stockholders on October 29, 2018. There were three participants in the second tranche; Crystal Amber, a related party, purchased 168,194,450 CDIs. All second tranche CDIs were allotted to investors in November 2018. Existing investors in the United States and Australia also purchased 23,819,450 and 5,208,350 CDIs, respectively. The securities sold in this private placement were issued in reliance on an exemption from the registration requirements of the Securities Act afforded by Rule 506 of Regulation D under the Securities Act with respect to purchasers who are U.S.-persons and Regulation S with respect to purchasers who are non-U.S. purchasers.

On March 15, 2019, the Company entered into a convertible note and warrant financing with Crystal Amber, in which the Company issued to Crystal Amber a Senior Unsecured Convertible Promissory Note in the aggregate principal amount of $1 million (the “March 2019 Note”). In connection with the issuance of the March 2019 Note, the Company also agreed to issue to Crystal Amber a warrant to purchase 78,984,823 CDIs at an initial exercise price of $0.0127 per CDI, subject to adjustment as described in the warrant, which warrant will expire on the fifth anniversary of the date of issuance (the “March 2019 Warrant”). Upon issuance, the March 2019 Warrant may be exercised at any time on a cash or cashless basis. If the Company issues securities in a subsequent financing at a per CDI price of less than $0.0127, the exercise price of the March 2019 Warrant will be reduced to the lowest such price per CDI (or the equivalent for shares of common stock) at which the newly issued securities were sold. The March 2019 Warrant, if and when issued, is expected to be issued in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended.

Item 6. Exhibits

See the Exhibit Index following the signature page to this Quarterly Report on Form 10-Q, which is incorporated by reference herein.

EXHIBIT INDEX

Exhibit No:		Description

10.1*		Third Amendment to Note ~~and Warrant~~ Purchase Agreement, dated ~~March~~June 15, ~~2019,~~2017, between ~~the Company~~GI Dynamics, Inc. and Crystal Amber Fund ~~Limited.~~Limited, as purchaser, dated April 30, 2019.

10.2*		Third Amendment to Senior ~~Unsecured~~Secured Convertible Promissory Note, dated ~~March~~June 15, ~~2019, issued by the Company to~~2017, between GI Dynamics, Inc. and Crystal Amber Fund ~~Limited.~~Limited, dated April 30, 2019.

10.3*		~~Second Amendment to~~ Note and Warrant Purchase Agreement, dated ~~June 15, 2017, by and~~May 8, 2019, between GI Dynamics, Inc. and Crystal Amber Fund Limited, as ~~purchaser, dated March 29, 2019.~~purchaser.

10.4*		~~Second~~Senior Unsecured Convertible Promissory Note, dated May 8, 2019, between GI Dynamics, Inc. and Crystal Amber Fund Limited.

10.5*		Warrant to Purchase 78,984,823 CHESS Depositary Interests of GI Dynamics, Inc., dated June 30, 2019, between GI Dynamics, Inc. and Crystal Amber Fund Limited.

10.6*		Warrant to Purchase up to 236,220,472 CHESS Depositary Interests of GI Dynamics, Inc., dated June 30, 2019, between GI Dynamics, Inc. and Crystal Amber Fund Limited.

10.7*		Fourth Amendment to Note Purchase Agreement, dated June 15, 2017, between GI Dynamics, Inc. and Crystal Amber Fund Limited, as purchaser, dated June 30, 2019.

10.8*		Fourth Amendment to Senior Secured Convertible Promissory Note, dated June 15, 2017, by and between GI Dynamics, Inc.~~, as payor,~~ and Crystal Amber Fund Limited, ~~as holder,~~ dated ~~March 29,~~June 30, 2019.

31.1*		Certification of principal executive officer pursuant to Rules 13a-14 or 15d-14 of the Exchange ~~Act~~Act.

31.2*		Certification of principal financial officer pursuant to Rules 13a-14 or 15d-14 of the Exchange ~~Act~~Act.

32.1‡		Certification of principal executive officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section ~~1350~~1350.

32.2‡		Certification of principal financial officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section ~~1350~~1350.

~~Table of Contents~~

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Database

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

*	Filed herewith.

‡	Furnished herewith.

†	~~Management contract or compensatory plan or arrangement.~~

2829

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	GI Dynamics, Inc.

Date: ~~May 16,~~August 14, 2019	By:	/s/ SCOTT W. SCHORER
		Scott W. Schorer
		President and Chief Executive Officer
		(principal executive officer)

Date: ~~May 16,~~August 14, 2019	By:	/s/ CHARLES R. CARTER
		Charles R. Carter Chief Financial Officer, Secretary
		(principal financial and accounting officer)

2930



Delaware		84-1621425
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

PO Box 51915
Boston, Massachusetts		02205
(Address of Principal Executive Offices)		(Zip Code)


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01	GID.ASX	Australia Securities Exchange

		Page
	PART I – FINANCIAL INFORMATION	1
Item 1.	Financial Statements (unaudited)	1
	Consolidated Balance Sheets as of ~~March 31,~~June 30, 2019 and December 31, 2018	1
	Consolidated Statements of Operations for the Three and Six Months Ended ~~March 31,~~June 30, 2019 and 2018	2
	Consolidated Statements of Stockholders’ Deficit for the Three and Six Months Ended ~~March 31,~~June 30, 2019 and 2018	3
	Consolidated Statements of Cash Flows for the ~~Three~~Six Months Ended ~~March 31,~~June 30, 2019 and 2018	4
	Notes to Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2022
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2527
Item 4.	Controls and Procedures	2627
	PART II – OTHER INFORMATION	2729
Item 1A.	Risk Factors	2729
Item 2.	Unregistered Sales of Equity Securities	2729
Item 6.	Exhibits	2729
	Signatures	2930

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

	As of June 30, 2019
	Operating Leases
	(in thousands)
Right-of-Use Assets	$	497
Liabilities
Short-term operating lease liabilities		179
Long-term operating lease liabilities		318
Total Liabilities	$	497

	Three months ended June 30, 2019			Six months ended June 30, 2019
	(in thousands)
Operating cash flows from operating leases in lease liability measurement	$	16		$	16
Operating cash flows from short term leases		92			92
Remaining long-term lease term in years		2.8			2.8
Discount rate		10	%		10	%

	Operating Leases
Year ending December 31,	(in thousands)
2019	$	95
2020		190
2021		195
2022		98
Total future minimum lease payments		578
Less: imputed interest		81
Total Liabilities	$	497